Drug induced pancreatitis: A systematic review of case reports to determine potential drug associations

Dianna Wolfe¹, Salmaan Kanji¹,², Fatemeh Yazdi¹, Pauline Barbeau¹, Danielle Rice¹, Andrew Beck¹, Claire Butler¹, Leila Esmaeilisaraji², Becky Skidmore¹, David Moher¹,³, Brian Hutton¹,³*

¹ Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada, ² Department of Pharmacy, The Ottawa Hospital, Ottawa, Ontario, Canada, ³ School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, Ottawa, Ontario, Canada

* bhutton@ohri.ca

Abstract

Objective

A current assessment of case reports of possible drug-induced pancreatitis is needed. We systematically reviewed the case report literature to identify drugs with potential associations with acute pancreatitis and the burden of evidence supporting these associations.

Methods

A protocol was developed a priori (PROSPERO CRD42017060473). We searched MEDLINE, Embase, the Cochrane Library, and additional sources to identify cases of drug-induced pancreatitis that met accepted diagnostic criteria of acute pancreatitis. Cases caused by multiple drugs or combination therapy were excluded. Established systematic review methods were used for screening and data extraction. A classification system for associated drugs was developed a priori based upon the number of cases, re-challenge, exclusion of non-drug causes of acute pancreatitis, and consistency of latency.

Results

Seven-hundred and thirteen cases of potential drug-induced pancreatitis were identified, implicating 213 unique drugs. The evidence base was poor: exclusion of non-drug causes of acute pancreatitis was incomplete or poorly reported in all cases, 47% had at least one underlying condition predisposing to acute pancreatitis, and causality assessment was not conducted in 81%. Forty-five drugs (21%) were classified as having the highest level of evidence regarding their association with acute pancreatitis; causality was deemed to be probable or definite for 19 of these drugs (42%). Fifty-seven drugs (27%) had the lowest level of evidence regarding an association with acute pancreatitis, being implicated in single case reports, without exclusion of other causes of acute pancreatitis.
Discussion

Much of the case report evidence upon which drug-induced pancreatitis associations are based is tenuous. A greater emphasis on exclusion of all non-drug causes of acute pancreatitis and on quality reporting would improve the evidence base. It should be recognized that reviews of case reports, are valuable scoping tools but have limited strength to establish drug-induced pancreatitis associations.

Registration
CRD42017060473.

Introduction

Acute pancreatitis (AP) is a common gastrointestinal cause of hospitalization, with over 230,000 cases per year leading to hospitalization in the United States [1]. Drug-related causes of AP are rare (0.1–2% of cases) [2], but occasionally can be life threatening. Knowledge of drugs with the potential to cause AP may aid in clinician awareness of this uncommon etiology, resulting in prevented re-administration of the offending medication and avoided patient harm.

Several publications have listed the drugs more commonly associated with AP [3–5,2,6,7]. However, a comprehensive review of the literature to identify drugs with potential associations has not been conducted since 2006 [7]. We aimed to update the previous systematic review of case reports by Badalov et al. [7] to develop a current list of drugs with potential associations with AP. However, early in our work we identified several limitations in the reporting of that review that prevented the performance of a formal review update. Consequently, a full systematic review of the case report literature from inception was performed to identify all rigorously diagnosed cases of AP that were suspected cases of drug-induced pancreatitis (DIP). With these data, we sought to classify the suspected drugs according to the level of evidence available upon which a potential association could be based.

Methods

A systematic review protocol was developed a priori and registered with PROSPERO (CRD42017060473). Our approach to data synthesis deviated from the protocol after we realized that the drug classification system used by Badalov et al. [7] was data driven and specific to the previous review, and that a more rigorous and global classification system was needed.

Research question addressed

This review addressed the following primary research question: "What drugs have potential associations with drug-induced pancreatitis? What level of evidence is available for these associations?"

Study eligibility criteria

The population-intervention-comparator-outcomes-study design (PICOS) framework was used to identify eligible cases. Details of the criteria established a priori were as follows:

- Population. Only human patients, with no restrictions on age or other demographics.
Intervention and comparator. Any drug that was suspected of causing acute pancreatitis in the reported case was of interest. Drug combinations were excluded (e.g., combination HIV therapy, cancer chemotherapy regimens). An exception was made for trimethoprim-sulfamethoxazole as these drugs are routinely administered in the same relative proportions. Where multiple drugs were administered prior to AP, we included cases in which the authors implicated an individual drug and excluded cases in which a combination of drugs or their interaction were suspected of causing the AP. We excluded herbal products, vaccines, poisons, and insecticides. Based on the criteria used by Badalov et al. [7], we limited inclusion to those cases that reported the name and dosage of the drug thought to cause the AP. No comparator was required.

Outcomes. We deviated from the review by Badalov et al [7] in that we included only cases that diagnosed acute pancreatitis (AP) using accepted criteria [8]. These criteria were initially published in 2006, the year in which Badalov et al. conducted their review. At least two of the following three features were required to be present for a diagnosis of AP to be upheld and a case included:

- Typical clinical symptoms (e.g., epigastric pain, nausea, vomiting);
- Serum amylase or lipase elevated at least three times the upper limit of normal (ULN). When the ULN was not reported, we used an ULN of 160 units/l for both amylase and lipase [9] (i.e., the reported amylase and/or lipase must have been >480 units/l for the criteria of serum amylase or lipase > three times the ULN to be accepted);
- Characteristic imaging findings of AP on contrast-enhanced computed tomography (CECT), on magnetic resonance imaging (MRI) or transabdominal ultrasonography. The etiologic cause of the AP must have been reported as being a drug exposure, with drug exposure occurring prior to the development of signs of AP. The time between initiation of drug administration and occurrence of AP (the latency) must have been reported. We did not discriminate according to the efforts that were undertaken to determine causality or the likelihood of the association. Cases suspected of having chronic pancreatitis with a drug-induced exacerbation were excluded.

Study design. We included only case reports and case series published in full text. Reviews of cases previously published in the literature were excluded to avoid case duplication. Letters to the editor were included, if all other criteria for inclusion were satisfied.

Searching the literature
An experienced medical information specialist (BS) developed and tested the search strategy using an iterative process in consultation with the review team. Another senior information specialist peer reviewed the strategy prior to execution using the PRESS Checklist [10]. We conducted several systematic reviews related to drug-induced pancreatitis concurrently and utilized the same base strategy for all. We performed separate searches for primary studies (for the concurrent systematic reviews) and case reports. Using the Ovid platform, we searched Ovid MEDLINE®, including Epub Ahead of Print and In-Process & Other Non-Indexed Citations, and Embase Classic+Embase. The Cochrane Library on Wiley, was also searched for primary studies alone. All database searches were performed on 31 January 2017, with a search update on 28 March 2019. We undertook a grey literature search of clinical practice guideline registries, the TRIP database, and Google Scholar on 9–10 March 2017.
We incorporated controlled vocabulary (e.g., “Pancreatitis/ci [chemically induced]”, “Drug-Related Side Effects and Adverse Reactions”) and keywords (e.g., “drug-induced pancreatitis”, “adverse effect”, “detection”) into the searches. We applied research design filters for both primary studies and case reports. Vocabulary and syntax were adjusted across the databases. No date or language limits were applied to either of the searches, but we removed animal-only and opinion pieces, where possible, from the results (opinion pieces retained for the case report search).

Specific details regarding the strategies are provided in S1 Text. References identified by the case report search were de-duplicated against the references identified in the primary study search to reduce reference screening load.

**Process of study selection**

A two-stage study selection process was used: all titles and abstracts were initially screened for potential relevance, with full texts of the potentially relevant references being screened subsequently. Screening at both stages was conducted independently by two reviewers, with included references requiring assessment by only one reviewer at Stage 1, but agreement of both reviewers required for inclusion at Stage 2. Agreement of both reviewers was required for exclusion at both stages. The online systematic review software DistillerSR (Evidence Partners Inc., Ottawa, Canada) was used to operationalize screening, using forms developed by the review team that were piloted prior to both stages of screening to maximize reviewer agreement. Conflicts were resolved by consensus, with consultation with a third independent reviewer if necessary.

**Data extraction and risk of bias assessment**

Data were extracted in Microsoft Excel (Microsoft Corp, Seattle, WA), using an extraction template that was initially piloted by two users on a set of five randomly selected case reports and adjusted as necessary. Five reviewers extracted data, and each conducted a pilot to improve agreement between extractors. Data were extracted by one reviewer and verified by a second reviewer.

Data elements collected during the extraction process included the following:

- Author, year of publication, and country of case;
- Patients’ key characteristics, including age, sex, underlying comorbidities, presence of renal dysfunction or other risk factors;
- Reported drug of association, including dosage and/or whether the case was an overdose related to a suicide attempt;
- Reported latency (i.e., the time from first drug exposure to the onset of symptoms of pancreatitis);
- Criteria for AP diagnosis, including presence/absence of typical symptoms, elevated amylase/lipase levels, and abnormalities on imaging, laparotomy, or autopsy;
- Exclusion of other causes of AP, including alcohol, biliary causes, hypertriglycerideridemia/hyperlipidemia, hypercalcemia, autoimmune causes, genetic causes, anatomic causes, trauma, viral causes, other drugs, and other causes;
- Presence/absence of a formal causality assessment; and
- Presence/absence of a re-challenge.
For data elements related to exclusion of other causes of AP, the extracted data were constrained to a set of predefined response options (i.e., “Yes,” “No,” “Unclear,” and blank), using the data validation tool in Excel. Constraint of response options at the data collection phase was considered necessary to simplify drug classification at the data synthesis phase, given the high number of included case reports expected. “Yes” was selected to indicate that a specific cause had been worked up and excluded. “No” was selected if a cause had been worked up and could not be excluded (e.g., hypertriglyceridemia at presentation that may have been present prior to drug exposure). Where a cause was worked up and the findings were not clearly interpretable, “Unclear” was selected. A blank response indicated the cause had not been reported in the publication. For each case report, the decision regarding whether a specific cause was excluded or not was based mainly upon the case report authors’ interpretation and their reported normal ranges (e.g., hypertriglyceridemia, hyperlipidemia, hypercalcaemia). If normal ranges were not provided, we referred to published sources [9]. We did not infer whether the non-drug causes had been worked up sufficiently to current standards to allow exclusion (e.g., whether currently accepted testing had been conducted to eliminate biliary causes, whether all relevant viruses had been eliminated with appropriate testing). Some non-drug causes required definition. Alcohol as a cause of AP was considered only to be chronic alcohol abuse or acute alcohol toxicity, as defined by the case report author, and not any alcohol use. Alcoholism as a cause was assumed to be excluded in patients under 18 years of age. A positive result for any autoimmune, genetic, or viral test elicited a “No” response for exclusion of that cause. However, when all autoimmune, genetic, or viral testing was negative, a “Yes” response was selected, regardless if all testing for that cause had been conducted. Any mention of family history of pancreatitis or hyperlipidemia, whether negative or positive, elicited a “Yes” or “No” response, respectively, regarding exclusion. Anatomic causes (e.g., irregularities of the pancreatic duct, pancreas divisum) were considered excluded if specifically mentioned as absent in imaging findings.

We critically scrutinized each case report in detail to make inferences as to whether other drugs were sufficiently excluded as a potential cause of the AP. We considered other drugs to have been excluded if (1) an effort had been made to report that other drugs were not associated (e.g., the authors stated that no AP case reports associated with the other drug(s) had been published to date); (2) the patient wasn’t taking other drugs; (3) the patient was taking other drugs but they were continued/restarted without a recurrence of AP; or (4) a formal causality assessment was conducted specific to the drug of interest (e.g., using Naranjo criteria [11]) that indicated that the drug of interest was the probable or definite cause and other drugs assessed with the same criteria were not. Other drugs were not considered to have been excluded if (1) the authors stated that they couldn’t exclude other drugs or (2) treatment with other drugs was temporally associated with an initial AP episode and AP recurred, while the patient was taking both the drug of interest and the other drug(s), with the authors not providing clear reasoning as to why the other drugs should be excluded. An “Unclear” response was warranted for all other cases.

Underlying diseases or conditions that may predispose a patient to AP were extracted, including the following: inflammatory bowel disease (i.e., Crohn’s disease and ulcerative colitis), diabetes mellitus, liver disease (e.g., any viral hepatitis, cirrhosis, cholangitis, liver transplant, Alagille’s Syndrome, signs of ascites and/or jaundice), HIV/AIDS, dyslipidemia (e.g., hypercholesterolemia, hypertriglyceridemia), immunologic disorders (e.g., rheumatoid arthritis, systemic lupus erythematosus, glomerulonephritis, bullous pemphigoid, autoimmune pancreatitis, optic neuritis), and renal dysfunction that could potentially lead to reduced drug clearance (e.g., end-stage renal disease, acute or chronic renal disease/insufficiency/failure, glomerulonephritis, lupus nephritis, IgA nephropathy, nephrotic syndrome, renal transplant
+, rejection, renal carcinoma, nephrolithiasis, prior drug nephrotoxicity, dialysis treatment, membranous glomerulopathy, metastatic involvement of kidney, nephrectomy, pyelonephritis, other renal insufficiency). The presence of an overdose, whether intentional or unintentional, was also extracted, although we did not compare the dose of the administered drug to current label dosages.

Data pertaining to formal causality assessment were extracted, including the name of the tool used and the outcome of the assessment. Following data extraction, case reports were manually screened for duplicates by sorting on patient and publication characteristics to ensure duplication was not present in our final database.

A tool has recently been proposed to assess the methodological quality of case reports and case series included in systematic reviews [12]. This tool proposes broad explanatory questions similar to the detailed criteria that we used either during study selection (e.g., only cases using accepted criteria for AP diagnosis and with complete reporting of drug dosage and latency were included) or to assess DIP causality in our included cases. Given that the questions in the tool considered most critical to assessment of methodological quality in our review context had already been assessed and accounted for, we elected not to conduct a separate risk of bias evaluation.

Summarizing the evidence

Descriptive statistics of publication characteristics and patient demographic variables were estimated. Case report data were grouped by the drug suspected to have caused the case of AP. Drugs were grouped, based on discussion with our clinical experts. Drugs were not separated by route of administration (e.g., oral and aerosolized pentamidine were considered the same drug). Oral contraceptives were grouped together, as the component combinations may be numerous and the mechanism of causing AP was likely the same. However, other single-component estrogen-like therapies were considered as separate medications (e.g., diethylstilbestrol). Asparaginase medications were grouped as some case reports did not clarify the type of asparaginase administered (e.g., obtained from Erwinia chrysanthemi versus Escherichia coli, pegylated versus non-pegylated asparaginase). Cases involving interferon alpha and beta were grouped separately, as were all corticosteroids (e.g., prednisone, prednisolone, dexamethasone, etc.).

Within each drug grouping, case reports were assessed according to the classification criteria described in Table 1. No validated classification criteria exist that assess the level of evidence of an association of a drug with AP. Our criteria were developed a priori by the review team, loosely based upon the data-driven classification system reported by Badalov et al. [7]. Because the Badalov system was derived from their review data and not developed a priori, there were classification gaps in which some drugs could fall if the system were to be used on a different set of data. The classification system used in the current review was structured to close these gaps. Additionally, our system has limited the impact of publication bias in the reporting of case reports (e.g., reporting of potential cases of DIP for some drugs may increase based upon perceptions of potential associations in the medical community). Drugs having multiple case reports associated with them are recognized as having a greater potential association than those with single case reports. However, beyond this, there is no arbitrary number of case reports required to increase the level of evidence of an association. Ultimately, we defined six drug classes based upon (1) evidence of a positive re-challenge, (2) a simplified measure of the rigour of the causality assessment conducted (i.e., whether three other main causes of AP—alcohol, biliary, and hypertriglyceridemia/hyperlipidemia—and all other drugs were conclusively ruled out as causes of DIP), and (3) the consistency of the latency for drugs for which
cases with a either a positive rechallenge or a rigorous causality assessment were not reported.

We used latency categories based upon those presented by Badalov et al. [7] (e.g., <24h, 1–30 days, >30 days), and have defined “consistent latency” as >75% of case reports for a drug falling into the same latency category. We conducted sensitivity analyses to evaluate (1) the impact of requiring positive imaging findings in the diagnosis of AP, and (2) the impact of requiring all ten causes of AP to be excluded instead of only four for a diagnosis of DIP in classes Ia and Ic. Classification of drugs was aided by the filtering tool in Excel (Microsoft Corp., Seattle, WA).

Latency data were categorized and the predominant latency category was identified for each drug (i.e., the latency category in which the majority of cases for each drug fell). The latency consistency of a drug was defined as the proportion of its cases that fell in its predominant latency category. Drugs represented by two cases that fell in two different latency categories were assigned a consistency of 0%.

### Reporting of review findings

The reporting in this manuscript was guided by the PRISMA Statement [13]. A completed PRISMA Checklist documents the completeness of reporting (see S2 Text).

### Results

A total of 596 publications were included, encompassing 713 unique cases and 213 unique drugs (Fig 1); detailed listings of included studies and excluded studies are provided in S3 Text and S4 Text, respectively. The characteristics of the included case reports and the

| Drug class | Definition |
|------------|------------|
| Class Ia   | • At least 1 case report in humans, with positive re-challenge  
• All other causes, such as alcohol, hypertriglyceridemia (and hyperlipidemia), gallstones, and other drugs are ruled out |
| Class Ib   | • At least 1 case report in humans, with positive re-challenge  
• Other causes, such as alcohol, hypertriglyceridemia, gallstones, and other drugs were not ruled out |
| Class Ic   | • At least 1 case report in humans, without a positive re-challenge (i.e., no re-challenge or a negative re-challenge)  
• Other causes, such as alcohol, hypertriglyceridemia, gallstones, and other drugs are ruled out |
| Class II   | • At least 2 cases in humans reported in the literature, without a positive re-challenge (i.e., no re-challenge or a negative re-challenge)  
• Consistent latency*  |
| Class III  | • At least 2 cases in humans reported the literature, without a positive re-challenge (i.e., no re-challenge or a negative re-challenge)  
• Inconsistent latency*  |
| Class IV   | • At least 1 case in humans reported the literature  
• Drugs not fitting into the earlier-described classes |

* “Consistent latency” defined as >75% of cases falling into the same latency category  
• Category 1: <24h.  
• Category 2: 1–30 days.  
• Category 3: >30 days.  

https://doi.org/10.1371/journal.pone.0231883.t001
Demographics of the included patients are presented in Table 2 and Table 3, respectively. The case report publication rate was highest from 1990 to 1999 (n = 241, 24.1 cases/year), and has slowed in recent years (2010–early 2019: 19.1 cases/year). In most case reports, the causes of AP that were excluded to arrive at a diagnosis of DIP were poorly reported, with only two recent case reports having data reported for all ten non-drug causes for which we extracted data [14,15]. Similarly, 81% of cases did not conduct a formal causality assessment. Overall, 182 of 190 re-challenges that were conducted resulted in a recurrence of AP (96%). However, re-challenge was not performed for most cases, with many citing the ethical concerns of knowingly re-administering a drug with the potential to cause a life-threatening condition.

Half of all cases (n = 358; 50%) had at least one primary underlying condition or risk factor for pancreatitis listed in Table 3. Thirty-nine percent (n = 275) had at least one primary underlying condition identified as necessary to rule out before a drug etiology should be considered. In addition, 53 patients (7%) had renal insufficiency and one (0.1%) had hepatosteatosis, which may alter drug clearance or metabolism, respectively, increasing the risk of adverse drug reactions; 47 patients (7%) had had a cholecystectomy, which may influence exocrine pancreatic dynamics; and 6 patients (0.8%) had had a previous episode of pancreatitis.
Table 2. Characteristics of the included case reports (n = 713).

| Characteristic | Cases (%) |
|----------------|-----------|
| **Year of publication** |           |
| 1960–69         | 6 (0.8)   |
| 1970–79         | 21 (2.9)  |
| 1980–89         | 80 (11.2) |
| 1990–99         | 241 (33.8)|
| 2000–2009       | 193 (27.1)|
| 2010–2019       | 172 (24.1)|
| **Country**     |           |
| USA             | 212 (29.7)|
| France          | 85 (11.9) |
| Spain           | 72 (10.1) |
| The Netherlands | 38 (5.3)  |
| Japan           | 34 (4.8)  |
| UK              | 29 (4.1)  |
| Italy           | 25 (3.5)  |
| India           | 24 (3.4)  |
| Canada          | 22 (3.1)  |
| Other           | 172 (24.1)|
| **Causes assessed as excluded to arrive at diagnosis of DIP** | |
| Alcoholism      |           |
| Excluded        | 547 (76.7)|
| Not excluded    | 14 (2.0)  |
| Unclear         | 12 (1.7)  |
| Not reported    | 140 (19.6)|
| Gallstones/biliary disease |     |
| Excluded        | 494 (69.2)|
| Not excluded    | 32 (4.5)  |
| Unclear         | 11 (1.5)  |
| Not reported    | 176 (24.7)|
| Hyperlipidemia/hypertriglyceridemia | |
| Excluded        | 304 (42.6)|
| Not excluded    | 58 (8.1)  |
| Unclear         | 7 (1.0)   |
| Not reported    | 344 (48.2)|
| Hypercalcemia   |           |
| Excluded        | 285 (40.0)|
| Not excluded    | 12 (1.7)  |
| Unclear         | 2 (0.3)   |
| Not reported    | 414 (58.1)|
| Autoimmune disease |       |
| Excluded        | 51 (7.2)  |
| Not excluded    | 4 (0.6)   |
| Unclear         | 5 (0.7)   |
| Not reported    | 653 (91.6)|
| Genetic causes or family history of AP | |
| Excluded        | 58 (8.1)  |
| Not excluded    | 4 (0.6)   |
| Unclear         | 2 (0.3)   |
| Not reported    | 649 (91.0)|
| Anatomic        |           |
| Excluded        | 54 (7.6)  |
| Not excluded    | 6 (0.8)   |
| Unclear         | 1 (0.1)   |
| Not reported    | 652 (91.4)|

(Continued)
Table 2. (Continued)

| Characteristic                  | Cases (%)                        |
|--------------------------------|----------------------------------|
| Trauma                         | Excluded: 113 (15.8)             |
|                                | Not excluded: 1 (0.1)            |
|                                | Unclear: 1 (0.1)                 |
|                                | Not reported: 598 (83.9)         |
| Viral                          | Excluded: 166 (23.2)             |
|                                | Not excluded: 16 (2.2)           |
|                                | Unclear: 4 (0.6)                 |
|                                | Not reported: 527 (73.9)         |
| Other drugs                    | Excluded: 492 (69.0)             |
|                                | Not excluded: 97 (13.6)          |
|                                | Unclear: 120 (16.8)              |
|                                | Not reported: 0 (0)               |

**Formal causality assessment conducted**

| Yes                           | 137 (19.2)                      |
| No                            | 576 (80.8)                      |

**Causality assessment tools used in case reports that assessed causality (n = 137)**

| Naranjo criteria*             | 68 (49.6)                      |
| Eland                        | 24 (17.5)                      |
| Delcenserie 2001             | 14 (10.2)                      |
| Mallory and Kern             | 11 (8.0)                       |
| Karch and Lasagna            | 10 (7.3)                       |
| Other French assessment toolsg | 8 (5.8)                       |
| Other toolsb                 | 6 (4.4)                        |

**Causality assessment findings in case reports that assessed causality (n = 137)**

| Definite/highly probable     | 17 (12.4)                      |
| Probable/likely              | 100 (73.0)                     |
| Probable/likely or possible  | 2 (1.5)                        |
| Possible/plausible           | 16 (11.7)                      |
| Doubtful                     | 2 (1.5)                        |

**Re-challenge conducted**

| Yes, and positive            | 182 (25.5)                     |
| Yes, and negative           | 8 (1.1)                        |
| No                           | 523 (73.4)                     |

* “Excluded” indicates that an effort was made by the authors to report that other drugs were not associated OR the patient wasn’t taking other drugs OR the patient was taking other drugs but they were continued/restarted without a recurrence of AP OR causality was assessed as “probable” for drug of interest.

b “Not excluded” indicates that the author stated that they couldn’t exclude other drugs OR the patient started taking other drugs at the time that the pancreatitis started.

c “Unclear” indicates that the patient was taking other drugs for a period prior to the AP and no comment was made regarding their possible association OR causality was assessed as “possible” for drug of interest.

d “Not reported” could not apply to any case because cases in which the impact of other drugs was not reported were categorized as “Unclear”.

e Three cases reported assessment findings for both Naranjo and WHO-UMC tools.

f All cases reporting using the Eland algorithm were published in the paper by Eland that described the causality assessment tool.

g Included Begaud et al (1985) (n = 6), Dangoumau et al. (1978) (n = 1), and Delcenserie et al. (1992) (n = 1).

h Included WHO-UMC assessment tool (n = 4), FDA algorithm (n = 1), and Kramer’s algorithm (n = 1).

https://doi.org/10.1371/journal.pone.0231883.t002
cholecystectomized patients had an opioid or opioid receptor agonist implicated (15%), four oral hypoglycemic agent implicated, and three a tetracycline derivative implicated. Four percent of DIP cases (n = 29) were due to intentional or unintentional overdose, with another

Table 3. Patient demographics of the included case reports (n = 713).

| Demographic | Cases (%) |
|-------------|-----------|
| **Patient age (years)** | |
| <1 | 1 (0.1) |
| 1–12 | 66 (9.3) |
| 13–18 | 62 (8.7) |
| 19–24 | 65 (9.1) |
| 25–64 | 396 (55.5) |
| >64 | 122 (17.1) |
| Not reported | 2 (0.3) |
| **Sex** | |
| Female | 339 (47.5) |
| Male | 373 (52.3) |
| Not reported | 1 (0.1) |
| **Primary underlying conditions that may predispose to AP** (one per patient, if present; n = 275) | |
| Crohn’s disease/inflammatiory bowel disease/ulcerative colitis | 78 (10.9) |
| Diabetes | 61 (8.6) |
| Genetic disorder (Class V Cystic Fibrosis mutation) | 2 (0.3) |
| Hepatitis | 27 (3.8) |
| HIV/AIDS b | 47 (6.6) |
| Hyperlipidemia/hypercholesterolemia/hypertriglyceridemia | 33 (4.6) |
| Immune disorder c | 26 (3.6) |
| Infection (malaria) | 1 (0.1) |
| **Other potential risk factors for AP or DIP** (multiple per patient possible) | Cases (%) |
| Previous cholecystectomy | 47 (6.6) |
| Previous episode of pancreatitis d | 6 (0.8) |
| Possible renal dysfunction e | 53 (7.4) |
| Hepatic disease f | 13 (1.8) |
| Gall stones/ biliary disease g | 32 (4.5) |
| History of moderate-to-heavy alcohol use or abuse | 14 (2.0) |

a Primary underlying conditions that were identified by our content experts as necessary to rule out before a diagnosis of DIP should be considered.

b Patients with HIV/AIDS often had other underlying infections.

c Includes rheumatoid arthritis, systemic lupus erythematosus, autoimmune skin disorders and glomerulonephritis, psoriatic arthritis, optic neuritis.

d Includes autoimmune, drug-induced, and gallstone-induced pancreatitis, as well as pancreatic carcinoma, etc.

e Includes acute/chronic renal insufficiency, end-stage renal disease, pyelonephritis, glomerulonephritis, glomerulopathy, nephrotic syndrome, nephrolithiasis, nephropathy, renal carcinoma, metastatic cancer, renal transplant rejection, etc. Renal function did not have to be tested for case to be flagged as possible renal dysfunction.

f Either hepatitis in addition to one of the above primary conditions or other hepatopathy, including HBV, HCV, previous biliary problems not treated by cholecystectomy, chronic active hepatitis, hepatocellular carcinoma, primary sclerosing cholangitis, and hepatosteatosis.

g Biliary disease was present or could not be ruled out at time of AP diagnosis.

https://doi.org/10.1371/journal.pone.0231883.t003

cholcystectomized patients had an opioid or opioid receptor agonist implicated (15%), four oral hypoglycemic agent implicated, and three a tetracycline derivative implicated. Four percent of DIP cases (n = 29) were due to intentional or unintentional overdose, with another
three cases being unclear as to whether there was an overdose. Ninety-eight cases (14%) did not fully report ruling out all other drugs as potential causes, calling into question the drug ultimately identified as the causative agent.

The 213 unique drugs implicated in the case reports were categorized according to our a priori classification scheme (Table 4). Similar numbers of drugs met the criteria of Classes Ia, Ib, and Ic (n = 45, 46, and 54, respectively). Most drugs with multiple case reports were categorized in these upper classes, with few remaining to be categorized as Class II (n = 6) or III (n = 5). More than a quarter of drugs were found in single case reports that did not have either exclusion of other causes of AP or a positive rechallenge and were categorized as Class IV (n = 57; 27%).

Negative re-challenge (i.e., no recurrence of AP upon re-administration of the drug) occurred in eight cases representing eight different drugs—all-trans retinoic acid, brentuximab vedotin, clozapine, interferon alpha, L-asparaginase, sorafenib, tacrolimus, and valproic acid— in different drug classes. All but brentuximab vedotin had been implicated in other case reports. Two of the eight cases with negative re-challenges were identified to have a “probable” association with the reported drug on using either the Naranjo criteria [11] or criteria of Delcenseri et al. [610] (brentuximab vedotin and L-asparaginase).

A drug-level summary of the identified case reports is provided in the review supplement (S5 Text), as is a comprehensive summary of the latency data associated with all agents and number of cases meeting the class criteria for each drug. A summary of key information for each of the drug classes (as outlined in Table 1) is provided in the following sections.

Identified Class Ia drugs

Forty-five drugs were classified as Class Ia from 344 case reports (48%), for a median of 4 case reports per drug (mean = 7.6; mode = 1; range = 1–56). Twelve drugs were included in Class Ia based on one case report each. The three drugs reported in the highest number of cases were valproic acid (n = 56), L-asparaginase (n = 34), and 5-ASA (n = 31). Predominant latency categories, in order of frequency of occurrence amongst the 45 drugs, were 1–30 days (n = 27 drugs), >30 days (n = 14 drugs), and <24 hours (n = 4 drugs). The median latency consistency amongst the 34 drugs with multiple case reports was 75%.

Causality was assessed for 25 drugs (56% of Class Ia drugs) in 64 cases (19% of Class Ia cases). Four drugs demonstrated less than probable likelihoods of causation that were assessed in single case reports: acetaminophen (likely), captopril (possible), tetracycline (possible), and valproic acid (plausible). All other drugs for which causality was assessed demonstrated probable or definite likelihood in at least one case report.

Forty-three percent of the 344 cases (n = 147) had an underlying condition that may have predisposed them to AP. Twenty-three cases (7%) had possible renal dysfunction that may have contributed to poor drug clearance and a predisposition to a drug reaction. Thirteen cases had both an underlying condition and renal dysfunction potentially predisposing them to both AP and a drug reaction.

Identified Class Ib drugs

Forty-six drugs were classified as Class Ib from 175 case reports (26%), for a median of 2 case reports per drug (mean = 3.9; mode = 1; range = 1–20). The three drugs reported in the highest number of cases were pentamidine (n = 20), stibogluconate (n = 18), and propofol (n = 12). Predominant latency categories, in order of frequency of occurrence amongst the 46 drugs, were 1–30 days (n = 30 drugs), >30 days (n = 14 drugs), and <24 hours (n = 2 drugs). The median latency consistency for the 31 drugs with multiple case reports was 80%.
Table 4. Drugs associated with DIP in the included case reports (n = 713).

| Class Ia (n = 45 drugs) | Class Ib (n = 46 drugs) | Class Ic (n = 53 drugs) | Class II (n = 6 drugs) | Class III (n = 5 drugs) | Class IV (n = 57 drugs) |
|------------------------|------------------------|-------------------------|------------------------|------------------------|------------------------|
| 5-acetylsalicylic acid (mesalamine); 31 cases | Amiodarone; 3 cases | **Adefovir dipivoxil; 1 case** | Ceftriaxone; 5 cases | **Acetylsalicylic acid; 3 cases** | **Ado-trastuzumab emtansine; 1 case** |
| (mesalamine); 31 cases | 39–41 | 42 | 43–47 | 38–40 | 30–32 |
| 6-mercaptopurine (6-MP); 6 cases | **Amoxicillin + clavulanic acid; 2 cases** | **Clofibrate; 2 cases** | Gold; 4 | **Albiglutide; 1 case** | |
| 6-mercaptopurine (6-MP); 6 cases | 51–55 | 16,27 | 58 | 39–61 | 62 |
| Acetaminophen; 9 | **Antilymphocyte globulin; 1 case** | **Artesunate 1 case** | **Exenatide; 3 cases** | **Nivolumab; 2 cases** | Alendronate; 1 case |
| Acetaminophen; 9 | 63–70 | 72 | 73–75 | 76,77 | 25 |
| All-trans retinoic acid; 3 | Carbamazepine; 5 | **Atorvastatin; 3 cases** | Isotretinoin; 3 | **Ondansetron; 2 cases** | **Amineptine; 1 case** |
| All-trans retinoic acid; 3 | 78–80 | 86–88 | 89–91 | 92,93 | 94 |
| Azathioprine; 29 | Captopril; 3 | **Bleomycin; 2 cases** | **Levetiracetam; 2 cases** | Tacrolimus; 2 | Benazepril; 1 |
| Azathioprine; 29 | 25,30,95–112 | 135,136 | 114,115 | 118,119 | 120 |
| Azodisalicylate/ olsalazine; 3 | Clomiphene; 2 | **Bocaprevir; 1 case** | **Sitagliptin; 3 cases** | **Brentuximab vedotin; 1 case** | |
| Azodisalicylate/ olsalazine; 3 | 25,121,122 | 123,124 | 128–128 | 129 | |
| Bezafibrate; 1 | **Clothiapine; 1 case** | **Bortezomib; 2 cases** | **Calcium carbonate; 1 case** | |
| Bezafibrate; 1 | 130 | 131 | 132,133 | 134 | |
| Captopril; 3 | Clozapine; 9 | **Canagliflozin; 2 cases** | **Calcium carbonate; 1 case** | |
| Captopril; 3 | 137–145 | 146,147 | 148 | 149,150 | 154 |
| Carbimazole; 2 | Cytarabine; 4 | **Candesartan; 1 case** | Chlorothalidone; 1 | 155 |
| Carbimazole; 2 | 149,150 | 151–153 | 154 | 155 |
| Cimeditine; 7 | Carbamazepine; 5 | **Celecoxib; 4 cases** | **Ciprofibrate; 1 case** | |
| Cimeditine; 7 | 25,156–160 | 162–165 | 25 | 26 |
| Codeine; 5 | Didanosine; 8 | Clarithromycin; 5 | **Ciprofibrate; 1 case** | 173–177 | 178 |
| Codeine; 5 | 166,167 | 168–172 | 179 | 180 | 181 |
| Dapsone; 3 | **Diphenoxylate + atropine; 1 case** | Danazol; 1 | **Clomipramine; 1 case** | |
| Dapsone; 3 | 179–181 | 182 | 183 | 184 | 185 |
| Erythromycin; 12 | **Eluxadoline 2 cases** | **Dexfenfluramine; 1 case** | **Clonidine; 1 case** | |
| Erythromycin; 12 | 185–196 | 197,198 | 199 | 200 | 201 |
| Fluvastatin; 1 | Enalapril; 1 | **Dciofenac; 2 cases** | **Dexamethasone; 1 case** | |
| Fluvastatin; 1 | 201 | 202–208 | 209,210 | 211 | 212–213 |
| Furosemide; 4 | **Everolimus; 2 cases** | **Diethylstilbestrol; 1 case** | **Doxylamine succinate; 1 case** | |
| Furosemide; 4 | 212–213 | 216,217 | 218 | 219 | 220–230 |
| Interferon-alpha; 12 | **Growth Hormone; 2 cases** | **Dilantin; 1 case** | **Ertapenem; 1 case** | |
| Interferon-alpha; 12 | 220–230 | 231,232 | 233 | 234 | 235–244 |
| Isoniazid; 10 | Hydrochlorothiazide; 2 | **Dimethyl fumarate; 1 case** | **Estramustine phosphate; 1 case** | |
| Isoniazid; 10 | 235–244 | 245,246 | 247 | 248 | 249–269 |
| L-asparaginase; 34 | Hydrocortisone; 1 | **Doxycycline; 4 cases** | **Famcyclovir; 1 case** | |
| L-asparaginase; 34 | 249–269 | 270 | 271–273 | 274 | 275–280 |
| Lisinopril; 6 | Ifosfamide; 4 | **Ezetimibe; 1 case** | **Gatifloxacin; 1 case** | |
| Lisinopril; 6 | 275–280 | 281–284 | 285 | 286 | 287–290 |
| Metformin; 4 | **Indalpine; 1 case** | **Finasteride; 1 case** | **Gemfibrozil; 1 case** | |
| Metformin; 4 | 287–290 | 291 | 292 | 293 | 294–299 |
| Methimazole; 6 | Lamivudine; 3 | **Flurbiprofen; 1 case** | **Granisetron; 1 case** | |
| Methimazole; 6 | 294–299 | 300,301 | 302 | 303 | 304–309 |
| **Methylprednisolone; 6** | Losartan; 3 | **Gadolinium; 3 cases** | **Interleukin-2; 1 case** | |
| **Methylprednisolone; 6** | 304–309 | 310–312 | 313–315 | 316 | 317–326 |
| Metronidazole; 11 | Mefenamic acid; 3 | **Glicazide; 1 case** | **Lacosamide; 1 case** | |
| Metronidazole; 11 | 25,317–326 | 327,328 | 329 | 330 | 331–333 |
| Nitrofurantoin; 3 | Meglumine antimoni ate; 5 | **Glimepiride; 1 case** | Lamotrigine; 1 | |
| Nitrofurantoin; 3 | 331–333 | 334–337 | 338 | 339 | 340 |
| Orlstat; 1 | Methylodopa; 3 | **Ibuprofen; 3 cases** | **Linagliptin 1 case** | |
| Orlstat; 1 | 340 | 341 | 342,343 | 344 | 345 |
| **Piroxicam; 1** | Mirtazapine; 4 | **Indomethacin; 2 cases** | **Linezolid 1 case** | |
| **Piroxicam; 1** | 345 | 346–349 | 350,351 | 352 | 353–354 |
| Pravastatin; 2 | Nelfinavir; 1 | **Interferon beta; 1 case** | **Lixisenatide 1 case** | |
| Pravastatin; 2 | 353–354 | 355 | 356 | 357 | 358–363 |
| Prednisone; 8 | Octreotide; 6 | **Irebesartan; 1 case** | **Loperamide; 1 case** | |
| Prednisone; 8 | 358–363 | 364–368 | 369 | 370 | 371,372 |
| Premarin; 2 | Omeprazole; 1 | **Itraconazole; 2 cases** | Lovastatin; 1 | |
| Premarin; 2 | 371,372 | 373 | 374 | 375 | (Continued)
Causality was assessed for 16 drugs (35% of Class Ib drugs) in 20 cases (11% of Class Ib cases). Three drugs demonstrated less than probable likelihoods of causation that were assessed in single case reports: clozapine, didanosine, and lamivudine were all assessed as possible. All other drugs for which causality was assessed demonstrated probable or definite likelihood in at least one case report.

**Table 4. (Continued)**

| Class Ia (n = 45 drugs) | Class Ib (n = 46 drugs) | Class Ic (n = 53 drugs) | Class II (n = 6 drugs) | Class III (n = 5 drugs) | Class IV (n = 57 drugs) |
|------------------------|------------------------|------------------------|-----------------------|------------------------|------------------------|
| Procaimamide; 1 [376]  | Oral contraceptive; 3  | **Ixazomib; 1 [379]**  | **Maprotiline; 1 [25]** |
| Pyritinol; 1 [380]     | Oxyphenbutazone; 2     | **Metandrostenolone; 1** [384] |
| Ramipril; 4 [206,385–387] | Paclitaxel; 4 [388–391] | **Micafungin; 1 [394]** |
| Ranitidine; 1 [395]    | **Paromomycin; 1 [396]** | **Mifepristone; 1 [399]** |
| Rosuvastatin; 1 [400]  | Pentamidine; 20 [401–417] | **Mizoribine; 1 [419]** |
| Simvastatin; 6 [420–424] | **Perindopril; 2 [425,426]** | **Montelukast; 1 [432]** |
| **Sorafenib; 7 [433–439]** | Prednisolone; 4 [440,441] | **Mycophenolate mofetil; 1 [443]** |
| Sulindac; 9 [25,444–450] | Propofol; 12 [15,451–460] | **Nifuroxazide; 1 [463]** |
| Tamoxifen; 6 [464–469]  | **Quetiapine; 2 [470,471]** | **Norfloxacin; 1 [475]** |
| “Telaprevir; 1 [476]” | “Rifaximin; 1 [477]” | **Pazopanib; 1 [480]** |
| Tetracycline; 5 [25,481–483] | Risperidone; 4 [484–487] | **Phenformin; 1 [491]** |
| **“Tigecycline; 10 [492–500]** | **Salazopyrine; 1 [501]** | **Phenolphthalein; 1 [504]** |
| “Thalidomide; 1 [505]” | **“Saxagliptin; 1 [506]** | **Polyethylene glycol bowel preparation; 1 [517]** |
| Trimepraprimsulfamethoxazole; 9 [518–526] | Stibogluconate; 18 [527–535] | **“Pantoprazole; 1 [536]** |
| “Venlafaxine; 1 [538]” | Sulfasalazine; 8 [63,122,539–543] | **“Pregabalin; 1 [537]** |
| Valproic acid; 56 [545–582] | **Riluzole; 3 [583–585]** | **“Rasburicase; 1 [586]** |
| “Valsartan; 1 [587]” | **“Rofecoxib; 2 [588,589]** | Rifampin; 1 [590]** |
| “Voriconazole; 1 [591]” | **“Secnidazole; 1 [592]** | Ritonavir; 1 [593]** |
| **“Sirolimus; 1 [594]** | **Roxithromycin; 1 [595]** |
| **“Theophylline; 1 [596]** | **Stavudine; 1 [597]** |
| “Tiaprofenic acid; 1 [598]” | **“Sunitinib; 1 [599]** |
| ““Tinidazole; 1 [600]** | **“Tacrolimus; 1 [601]** |
| ““Vedolizumab; 1 [602]** | **“Telmisartan; 1 [603]** |
| “Vildagliptin; 2 [431,604]” | **“Tocilizumab; 1 [605]** |
| **“Ursodeoxycholic acid; 1 [606]** |
| **“Venlafaxine; 1 [607]** |
| **“Zidovudine 1 [608]** |
| **“Ziprasidone; 1 [609]** |

Numbers of cases indicate the total cases identified for the drug; however, not all cases may have met the drug class criteria. Multiple cases may have been reported in a single reference, therefore, the number of citations may not equal the number of cases for each drug. See the supplement (S5 Text) for a detailed summary of each drug.

**New drug; association not reported by Badalov et al. [7].**

https://doi.org/10.1371/journal.pone.0231883.t004

Causality was assessed for 16 drugs (35% of Class Ib drugs) in 20 cases (11% of Class Ib cases). Three drugs demonstrated less than probable likelihoods of causation that were assessed in single case reports: clozapine, didanosine, and lamivudine were all assessed as possible. All other drugs for which causality was assessed demonstrated probable or definite likelihood in at least one case report.
Forty-one percent of the 175 cases (n = 72) in the Class Ib category had an underlying condition that may have predisposed them to AP. Twelve cases (7%) had underlying renal dysfunction that may have contributed to poor drug clearance and a predisposition to a drug reaction. Five cases had both an underlying condition and renal dysfunction potentially predisposing them to both AP and a drug reaction.

**Identified Class Ic drugs**

Fifty-three drugs were classified as Class Ic from 106 case reports (15%), for a median of 1 case report per drug (mean = 2.0; mode = 1; range = 1–10). The four drugs reported in the highest number of cases were olanzapine (n = 10), clarithromycin (n = 5), liraglutide (n = 5), and minocycline (n = 5). Predominant latency categories, in order of frequency of occurrence amongst the 53 drugs, were 1–30 days (n = 31 drugs), >30 days (n = 19 drugs), and <24 hours (n = 10 drugs). The median latency consistency for the 26 drugs with multiple case reports was 71%.

Causality was assessed for 24 drugs (45% of Class Ic drugs) in 37 cases (35% of Class Ic cases). The following drugs demonstrated only possible likelihood of causation in at least one case report: clarithromycin, liraglutide, minocycline, nilotinib, and riluzole. All other drugs for which causality was assessed demonstrated probable or definite likelihood in all assessed case reports.

Thirty-five percent of the 94 cases (n = 33) in the Class Ic category had an underlying condition that may have predisposed them to AP. Thirteen cases (25%) had had a previous cholecystectomy. Ten cases (19%) had underlying renal dysfunction that may have contributed to poor drug clearance and a predisposition to a drug reaction. Four cases had both an underlying condition (diabetes) and renal dysfunction potentially predisposing them to both AP and a drug reaction.

**Identified Class II drugs**

Six drugs were classified as Class II from 18 case reports (3%), including ceftriaxone (n = 5 cases), exenatide (n = 3), isotretinoin (n = 3), sitagliptin (n = 3), clofibrate (n = 2), and levetiracetam (n = 2). Three drugs had a predominant latency category of 1–30 days and three had a predominant latency category of >30 days. By definition for this drug class, all drugs had 100% latency consistency.

Causality was assessed for two drugs, exenatide and levetiracetam, both of which demonstrated probable likelihood of causation.

Ten of the 18 cases (56%) in the Class II category had at least one underlying condition that may have predisposed them to AP. Three cases (17%) had underlying renal dysfunction that may have contributed to poor drug clearance and a predisposition to a drug reaction. Two cases had both an underlying condition and renal dysfunction potentially predisposing it to both AP and a drug reaction. Four patients (22%) had had a cholecystectomy.

**Identified Class III drugs**

Five drugs were classified as Class III from 13 case reports (2%), including gold (n = 4), acetylsalicylic acid (n = 3), nivolumab (n = 2), ondansetron (n = 2), and tacrolimus (n = 2). Latency consistency was 0% for the three drugs with two case reports each (i.e., both cases for each drug had different latencies); for the other two drugs, the median latency consistency was 71%.

Causality was assessed for one drug, tacrolimus, which demonstrated a probable likelihood of causation for one case.
The four cases with DIP due to gold had an immune disorder (all rheumatoid arthritis) that may have predisposed them to AP. No other cases had an underlying illness associated with AP or had reported risk factors for AP.

**Identified Class IV drugs**

Fifty-seven drugs were classified as Class IV from single case reports (27% of all drugs; 8% of all cases). Latency was 1–30 days for 31 drugs, >30 days for 19 drugs, and <24 hours for 7 drugs. Re-challenge was conducted in one case report and was negative (brentuximab vedotin). Causality was assessed for 15 drugs (26% of Class IV drugs). Three drugs demonstrated less than probable likelihood of causation: alendronate, calcium carbonate, and ciprofibrate, all of which were assessed as possible. All other drugs for which causality was assessed demonstrated probable likelihood of causation.

Twenty-three of the 57 cases (40%) in the Class IV category had at least one underlying condition that may have predisposed them to AP. Two of these cases had multiple conditions associated with AP. Three cases (5%) had had a previous cholecystectomy. Five cases (9%) had underlying renal dysfunction that may have contributed to poor drug clearance and a predisposition to a drug reaction. Two cases had both an underlying condition and renal dysfunction potentially predisposing them to both AP and a drug reaction.

**Sensitivity analyses**

When more stringent diagnostic criteria for AP were applied to the included cases (i.e., positive imaging), 429 of 713 cases (60%) met the restricted criteria, implicating 160 of 213 drugs (75%). The following numbers of drugs were found in each class:

- **Class Ia**: 31 drugs (from 45 drugs before imaging restriction)
- **Class Ib**: 33 drugs (from 46), four of which had been Class Ia drugs (all-trans-retinoic acid, cimetidine, interferon alpha, and thalidomide)
- **Class Ic**: 43 drugs (from 53), two of which had been Class Ia drugs (erythromycin and olsalazine) and two of which had been Class Ib drugs (amiodarone and paclitaxel)
- **Class II**: five drugs (from 6), one of which had been a Class Ib drug (stibogluconate)
- **Class III**: six drugs (from 5), two of which had been Class Ib drugs (carbamazepine and pentamidine)
- **Class IV**: 42 drugs (from 57), two of which had been Class Ia drugs (prednisone and sulindac), two of which had been Class Ib drugs (oxyphenbutazone and risperidone), three of which had been Class Ic drugs (bortezomib, metolazone, and naltrexone), and one of which had been a Class II drug (levetiracetam).

Fifty-three drugs were no longer associated with DIP, when cases were restricted to require positive imaging. Of these drugs, six were Class Ia (bezafibrate, metronidazole, orlistat, procaainamide, ranitidine, and vemurafenib), eleven each were Class Ib and Class Ic, one each were Class II and III, and the remaining 23 were Class IV. More detailed lists of drugs from this sensitivity analysis can be found in the supplement ([S6 Text](#)).

When we required all ten causes of AP to be excluded instead of only four for a diagnosis of DIP, only two recently published cases met the more rigorous diagnostic criteria for DIP [14,15]. These two cases implicated amoxicillin/clavulanic acid and propofol, respectively. None of the remaining 711 cases met the more stringent DIP diagnostic criteria.
Discussion

Several works have been published that have reviewed drugs associated with acute pancreatitis, both narratively and systematically [3–7], the most recent of which was published by Badalov et al. in 2007 [7]. Our initial goal was to update this review; however, early in the review we identified limitations in the reporting of the previous review’s methods that prevented the conduct of a simple update. Consequently, we undertook a full systematic review of the case report literature, in its entirety, using rigorous systematic review methods. Our search strategy differed from that of Badalov et al. [7] in that we searched multiple databases, and ultimately included English, French, and Spanish publications. We used more strict screening criteria initially to capture only cases of AP based upon currently accepted diagnostic criteria [8], which corresponded to the “definite” and “probable” cases ultimately analyzed by Badalov et al [7]. However, we excluded cases in which a combination of drugs was the attributed cause of DIP, while Badalov et al. retained them. To synthesize the case reports, we adjusted the drug classification scheme proposed by Badalov et al., making all drug classes mutually exclusive. For classes II–IV, the revised scheme eliminated the classification criteria based upon arbitrary numbers of case reports published for a drug and focused instead on whether multiple (Classes II and III) or single (Class IV) case reports had been published. Our review identified substantially more drugs potentially associated with AP.

While a large number of drugs with potential associations with AP were identified in this review, these potential associations were based upon (a) cases that may not have had AP, and (b) cases of AP that had not completely excluded all non-drug causes of AP. All cases included in our review met currently accepted criteria for AP diagnosis; however, when more stringent diagnostic criteria were applied for the diagnosis of AP (i.e., positive imaging), the number of drugs associated with AP dropped by 25% (n = 160), suggesting that more rigorous evidence is required to confirm associations. Secondly, in our drug classification scheme, as partial assessment of causality, we followed the criteria proposed by Badalov et al. [7] and required exclusion of only four other causes of AP (i.e., alcohol, hypertriglyceridemia/hyperlipidemia, gallstones, and other drugs) rather than requiring exclusion of the remaining six non-drug causes proposed by our content experts (i.e., hypercalcemia, genetic/hereditary, anatomic, trauma, viral, and autoimmune causes). Had we required exclusion of all non-drug causes, only two drugs would have met the criteria of Classes Ia or Ic. In other words, the diagnosis of DIP was not conclusive in any of the 711 cases identified by authors as DIP in the literature. This sensitivity analysis demonstrates the tenuous level of evidence upon which DIP associations are often based and the contribution of comorbid conditions.

Awareness of all other possible non-drug causes of AP amongst clinicians may also influence formal causality assessment. The Naranjo algorithm, the most frequently encountered causality assessment tool in our set of included case reports, includes an assessment of whether all alternative etiologies of AP were excluded. However, if clinicians are unaware of all possible alternative causes of AP or the appropriate tests for their exclusion, then the final Naranjo score that determines the probability of causation may be inflated. Similarly, the probability of causation may be inflated when the prior probability of the event is not considered [611] (e.g., consideration of an inherent increased risk of AP in a patient due to factors such as the underlying disease for which the drug was administered, comorbidities, or concomitant drugs, and interactions of these factors). As well, valuable information regarding these other risk factors may be lost, if causation is distilled down to a simple probability level in causality assessment. Like a causality assessment, our drug classification system considers re-occurrence of AP upon re-challenge indicative of a higher level of evidence of an association. However, ethical concerns often prevent clinicians from knowingly reinitiating treatments suspected of causing
potentially life-threatening conditions like DIP. In our classification system, the absence of a positive re-challenge may occur for one of two reasons—no re-challenge was conducted or the presence of a negative re-challenge. However, our system did not penalize drugs that had a case with a negative re-challenge. We must recognize some of the limitations of causality assessment and not over-interpret the findings.

The complex relationships amongst underlying diseases, comorbidities, and concomitant drugs, as well as the difficulty in excluding all non-drug causes of AP and the constraints on re-challenge make final diagnosis of DIP extremely difficult. Case reports and the associations generated from their synthesis should be recognized as fallible. The evidence base upon which associations between drugs and AP are made could be bolstered through systematic review of observational studies or randomized controlled trials (RCTs) of individual drugs identified by case report review as having potential associations with AP. In RCTs, the control arm of patients with similar underlying diseases, comorbidities, and concomitant medications as those in the drug intervention arm reduces or eliminates the effects of these factors. Thus, the risk of AP due to the suspected drug is more easily discerned through the confounding factors and often is different from that gleaned from case report data. For example, an association between oral hypoglycemics and AP has been speculated based upon numerous published case reports [73–75,126,159,287–290,427–431,491,506,604]; however, systematic review and/or meta-analysis of trial data have demonstrated no association with AP for vildagliptin alone [612] or for dipeptidyl peptidase-4 inhibitors (DPP4i) as a group (i.e., vildagliptin, sitagliptin, saxagliptin, alogliptin, linagliptin, and dutagliptin) [613]. Another systematic review of various study designs concluded that AP during oral hypoglycemic therapy was a rare event and that if an association exists, it is not as strong as originally thought [614]. Similarly, meta-analyses of cohort and case-control study data have been recently published, refuting an association between statins and AP, of which several were implicated in our review [615]. Given recent efforts to evaluate associations between individual drug categories and AP, we considered categorizing the drugs implicated in our review by the AHFS system. However, ultimately, we consciously elected not to categorize and risk potentially promoting inferences about specific drug categories that were based upon low-quality evidence. Instead, we encourage the reader to explore the raw data set as well as the supplement available online.

There are strengths and limitations of the current review to be noted. In terms of strengths, we have ensured that the methods of our systematic review have been transparently reported to facilitate future updating within this area of active publication. We updated the study selection criteria of the previously published review [7] by including only those case reports that satisfied the Atlanta criteria for AP diagnosis [8]. However, we retained the previous review’s requirement to exclude cases for which drug dosages were not reported, which may have restricted the volume of data available for synthesis to some degree. As well, while we excluded cases for which the implicated cause was a combination of drugs, in our included cases, it is possible that other drugs taken in proximity to or concurrently with the drug implicated by the authors could have made the patient more susceptible to the effects of the implicated drug. The same patient taking the same drug without exposure to another drug may not have experienced AP. As a strength, our drug classification system has eliminated some ambiguity in the previous system that was based upon the data extracted [7]. However, the classification system has some limitations. Firstly, we did not assess the testing methods used in case reports to exclude non-drug causes of AP because these data were often poorly reported. As such, older cases may have been misdiagnosed as DIP because the available testing wasn’t sufficiently sensitive to identify some non-drug causes of AP, such as biliary sludge and crystal formation. Secondly, the classification system does not consider patients’ underlying diseases. Some conditions for which drugs are administered may predispose patients to develop AP (e.g., HIV/
AIDS [5]) or be susceptible to drug-induced adverse events (e.g., renal dysfunction). Almost half of all cases included in this review had an underlying disease that may have predisposed them to AP. We have presented data regarding the presence of underlying conditions to guide readers. Finally, drugs implicated in multiple case reports were classified based upon the case report meeting the highest criteria for classification, rather than the median class for the group. With this method of classification, drugs can never be demoted as further case reports are published, a potential limitation for updating the review. Future updates may need to consider data from study designs other than case reports (e.g., meta-analyses of adverse event data from trials) for drugs with demonstrated ambiguous associations (e.g., oral hypoglycemics). However, it should be noted that while meta-analysis of adverse event data from RCTs may help to discern the relationship between a drug and DIP, these analyses are often limited by the complexity of diagnosis of AP and the lack of detailed reporting of adverse events within these trials. Finally, while this review incorporated extensive efforts to find a large amount of information to be dissected to meet our objectives, it must be kept in mind that the type of evidence reviewed (i.e., case reports) remains at the bottom of the hierarchy of evidence and, thus, has inherent limitations for inferences.

Conclusions
Although the rate of publication of case reports has lowered in the past decade, we continue to identify drugs with new associations with AP and new evidence to bolster or refute previously suspected associations. Much of the case report evidence upon which DIP associations are based is tenuous. A greater emphasis on exclusion of all non-drug causes of AP and on quality reporting would improve the evidence base considerably. However, even with improvements in methods and reporting, it should be recognized that case reports remain the lowest level in the hierarchy of evidence [616], and that case report reviews, although valuable scoping tools of the published post-market evidence, should be recognized as having limited strength in the establishment of associations between drugs and AP.

Supporting information
S1 Text. Literature search strategy.
(DOCX)

S2 Text. Completed PRISMA checklist.
(DOCX)

S3 Text. List of included studies.
(DOCX)

S4 Text. List of excluded studies.
(DOCX)

S5 Text. Detailed summary table–drugs associated with drug induced pancreatitis.
(DOCX)

S6 Text. Sensitivity analysis–positive imaging findings required for a diagnosis of DIP.
(DOCX)

S1 Data. Collection of extracted data.
(XLSX)
Acknowledgments

We wish to thank Raymond Daniel for his indispensable support in reference acquisition and database management throughout the conduct of this review.

Author Contributions

Conceptualization: Salmaan Kanji, Brian Hutton.

Data curation: Dianna Wolfe, Fatemeh Yazdi, Pauline Barbeau, Danielle Rice, Andrew Beck, Claire Butler, Leila Esmaeilsaraji.

Formal analysis: Dianna Wolfe, Brian Hutton.

Funding acquisition: David Moher, Brian Hutton.

Methodology: Dianna Wolfe, Salmaan Kanji, Danielle Rice, Becky Skidmore, David Moher, Brian Hutton.

Project administration: Brian Hutton.

Resources: Fatemeh Yazdi, Pauline Barbeau, Danielle Rice, Claire Butler, Leila Esmaeilsaraji, Becky Skidmore, Brian Hutton.

Software: Becky Skidmore.

Supervision: Salmaan Kanji, Brian Hutton.

Validation: Fatemeh Yazdi, Pauline Barbeau, Andrew Beck, Claire Butler, Leila Esmaeilsaraji, Brian Hutton.

Visualization: Dianna Wolfe.

Writing – original draft: Dianna Wolfe, Brian Hutton.

Writing – review & editing: Dianna Wolfe, Salmaan Kanji, Fatemeh Yazdi, Pauline Barbeau, Danielle Rice, Andrew Beck, Claire Butler, Leila Esmaeilsaraji, Becky Skidmore, David Moher, Brian Hutton.

References

1. Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, et al. Burden of Gastrointestinal Disease in the United States: 2012 Update. Gastroenterology. 2012; 143: 1179–1187.e3. https://doi.org/10.1053/j.gastro.2012.08.002 PMID: 22885331

2. Jones MR, Hall OM, Kaye AM, Kaye AD. Drug-induced acute pancreatitis: a review. Ochsner J. 2015; 15: 45–51. PMID: 25829880

3. Mallory A, Kern F. Drug-induced pancreatitis: a critical review. Gastroenterology. 1980; 78: 813–820. PMID: 6986321

4. Underwood TW, Frye CB. Drug-induced pancreatitis. Clin Pharm. 1993; 12: 440–448. PMID: 8403815

5. McArthur KE. Review article: drug-induced pancreatitis. Aliment Pharmacol Ther. 1996; 10: 23–38. https://doi.org/10.1111/j.1365-2036.1996.tb00174.x PMID: 8871441

6. Trivedi CD, Pitchumoni CS. Drug-induced pancreatitis: an update. J Clin Gastroenterol. 2005; 39: 709–716. https://doi.org/10.1097/01.mcg.0000173929.60115.b4 PMID: 16082282

7. Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S. Drug-Induced Acute Pancreatitis: An Evidence-Based Review. Clin Gastroenterol Hepatol. 2007; 5: 649–661.e3. https://doi.org/10.1016/j.cgh.2006.11.023 PMID: 17395548

8. Banks PA, Boilen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013; 62: 102–111. https://doi.org/10.1136/gutjnl-2012-302779 PMID: 23100216

9. Medical Council of Canada. Clinical Laboratory Tests—Normal Values. [cited 22 Fe 2018]. Available: http://mcc.ca/objectives/normal-values/
10. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of Electronic Search Strategies: 2015 guideline statement. J Clin Epidemiol. 2016; 75: 40–6. https://doi.org/10.1016/j.jclinepi.2016.01.021 PMID: 27005575

11. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30: 239–245. https://doi.org/10.1038/cpit.1981.154 PMID: 7249508

12. Murad MH, Sultan S, Haffar S, Bazerbach F. Methodological quality and synthesis of case series and case reports. BMJ Evid-Based Med. 2018; 23: 60–63. https://doi.org/10.1136/bmjebm-2017-110853 PMID: 29420178

13. Moher D, Liberati A, Tetzlaff J, Altman D, group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2008; 6.

14. Chams S, El Sayegh S, Hamd on M, Kumar S, Tegeltija V. Amoxicillin/clavulanic acid-induced pancreatitis: case report. BMC Gastroent erol. 2018; 18: 122. https://doi.org/10.1186/s12876-018-0851-6 PMID: 28393377

15. Csomor J, Murinová I, Brouliková K, Kučerka O, Sedloň P, Jarosˇek J, et al. Propofol-induced acute pancreatitis. J Clin Pharm Ther. 2017; 42: 495–498. https://doi.org/10.1111/jcpt.12524 PMID: 28393377

16. Adachi E, Okazaki K, Matsushima Y, Seno H, Uchida K, Nakase H, et al. Acute pancreatitis secondary to 5-aminosalicylic acid therapy in a patient with ulcerative colitis. Int J Pancreatol Off J Int Assoc Pancreatol. 1999; 25: 217–221.

17. Al-Zayani J. Acute pancreatitis associated with the use of 5-aminosalicylic acid and sulfasalazine in a patient with ulcerative colitis. J Bahrain Med Soc. 1997; 9: 55–59.

18. Arai Y, Anhiro S, Ida D, Odag i I, Itagaki M, Komoike N, et al. Acute Pancreatitis due to pH-Dependent Mesalazine That Occurred in the Course of Ulcerative Colitis. Case Rep Gastroenterol. 2011; 5: 610–616. https://doi.org/10.1159/000333605 PMID: 22110423

19. Asma OK, Dail la G, Asma K, Norsaf B, He LE, Dorra T, et al. Acute pancreatitis secondary to Long-Term 5-Aminosalicylic acid therapy in a patient with ulcerative colitis: A case-report. Tunis Med. 2014; 92: 423.

20. Besseau M, Delchier JC, Blazquez M, Soule JC. Acute pancreatitis induced by mesalazine (Pentasa) [7]. Gastroenterol Clin Biol. 1991; 15: 174–175.

21. Daniel F, Seksik P, Cacheux W, Jian R, Marteau P. Toleranc e of 4-aminosalicylic acid enemas in patients with inflammator y bowel disease and 5-aminosalicylic-induced acute pancreatitis. Inflamm Bowel Dis. 2004; 10: 258–260. https://doi.org/10.1097/00054725-200405000-00013 PMID: 15290921

22. Decocq G, Gras-Champel V, Vrolant-Mille C, Delcenserie R, Sauve L, Masson H, et al. [Acute pancreatitis induced by drugs derived from 5-aminosalicylic acid: case report and review of the literature]. Therapie. 1999; 54: 41–48. PMID: 10216421

23. Degrez P, Descamps C, Flasse R. Pancreatitis induced by 5-aminosalicylic acid. Lancet Lond Engl. 1989; 2: 445–446.

24. Eland IA, van Puijenbroek EP, Sturkenboom MJ, Wilson JH, Stricker BH. Drug-associated acute pancreatitis: twenty-one years of spontaneous reporting in The Netherlands. Am J Gastroenterol. 1999; 94: 2417–2422. https://doi.org/10.1111/j.1572-0241.1999.01367.x PMID: 10484002

25. Erdkamp F, Houben M, Ackerman E, Breed W, van Spreeuwell J. Pancreatitis induced by mesalazine [6]. J Clin Gastroenterol. 1994; 19: 348–349. https://doi.org/10.1097/00004836-199412000-00024 PMID: 7876525

26. Eland IA, van Puijenbroek EP, Sturkenboom MJ, Wilson JH, Stricker BH. Drug-associated acute pancreatitis: twenty-one years of spontaneous reporting in The Netherlands. Am J Gastroenterol. 1999; 94: 2417–2422. https://doi.org/10.1111/j.1572-0241.1999.01367.x PMID: 10484002

27. Fernandez J, Sala M, Panes J, Feu F, Navarro S, Teres J. Acute pancreatitis after long-term 5-aminosalicylic acid therapy. Am J Gastroenterol. 1997; 92: 2302–2303. PMID: 9399776

28. Fiorentini MT, Fracchia M, Galatola G, Barlotta A, de la Pierre M. Acute pancreatitis during oral 5-aminosalicylic acid therapy. Dig Dis Sci. 1990; 35: 1180–1182. https://doi.org/10.1007/bf01537594 PMID: 2390934

29. Hochain P, Guedon C, Colin R. Acute pancreatitis as a complication of Crohn’s disease treated by oral mesalamine [6]. Gastroenterol Clin Biol. 1991; 15: 173–174.

30. Inoue H, Shiraki K, Okano H, Deguchi M, Yamanaka T, Sakai T, et al. Acute pancreatitis in patients with ulcerative colitis. Dig Dis Sci. 2005; 50: 1064–1067. https://doi.org/10.1007/s10620-005-2705-7 PMID: 15986855

31. Mari B, Brulet E, Campo R, Bustamante E, Bombardo J. Acute pancreatitis by 5-aminosalicylic acid [2]. Gastroenterol Hepatol. 1999; 22: 28–29.
32. Paul AC, Oommen SP, Angami S, Moses PD. Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy. Indian J Gastroenterol Off J Indian Soc Gastroenterol. 2000; 19: 195–196.

33. Radke M, Bartolomeus G, Muller M, Richter I. Acute pancreatitis in Crohn’s disease due to 5-ASA therapy. J Pediatr Gastroenterol Nutr. 1993; 16: 337–339. https://doi.org/10.1097/00005176-199304000-00022 PMID: 8492268

34. Romero Castro R, Jimenez Saenz M, Galanopoulou G, Tzivras M, Archimandritis A. Acute pancreatitis after long-term therapy with mesalazine, and hyperamylasaemia associated with azathioprine in a patient with ulcerative colitis. Eur J Gastroenterol Hepatol. 2003; 15: 933–934. https://doi.org/10.1097/00042737-200308000-00019 PMID: 12867808

35. Tran K, Froguel E, Jian R, Lemann M, Modigliani R. Acute pancreatitis induced by mesalazine. J Gastroenterol. 1991; 13: 715–716. https://doi.org/10.1097/00004836-199112000-00021 PMID: 1761847

36. Meczker Á, Mikó A, Hegyi P. 5-ASA induces mild acute pancreatitis. Case report and review of the literature. J Gastrointest Liver Dis JGLD. 2018; 27: 189–194. https://doi.org/10.15403/jgld.2014.1121.272.asa PMID: 29922764

37. Zinberg J, Chernai R, Coman E, Rosenblatt R, Brandt LJ. Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis. Am J Gastroenterol. 1991; 86: 1251–1254. PMID: 1882806

47. Nakagawa N, Ochi N, Yamane H, Honda Y, Nagasaki Y, Urata N, et al. Ceftriaxone-associated pancreatitis captured on serial computed tomography scans. Radiol Case Rep. 2018; 13: 43–46. https://doi.org/10.1016/j.radcr.2017.10.022 PMID: 29487636

52. Cappell MS, Das KM. Rapid development of pancreatitis following reuse of 6-mercaptopurine. J Clin Gastroenterol. 1989; 11: 679–681. https://doi.org/10.1097/00004836-198912000-00017 PMID: 2584670

53. Nogueira Soriano JM, Pelaez DG, Abd MA, Esteban CJ. Acute pancreatitis produced by 6-mercaptopurine in a patient with Crohn disease. Gastroenterol Hepatol. 1991; 14: 44–45.
54. Targarona EM, Munoz E, Puig J, Marco C. [Acute pancreatitis secondary to the administration of 6-mercaptopurine]. Med Clin (Barc). 1990; 95: 116–117.

55. Eddoukani I, Oubah S, Samlani Z, Krati K. Pancréatite aigue secondaire à la 6-mercaptopurine: à propos d’un cas. J Afr Hépato-Gastroentérologie. 2016; 10: 220–222. https://doi.org/10.1007/s12157-016-0679-z

56. Hanline MHJ. Acute pancreatitis caused by ampicillin. South Med J. 1987; 80: 1069. https://doi.org/10.1097/00007611-198708000-00049 PMID: 3303361

57. Galindo C, Buenestado J, Rene Espinet JM, Pinol MC. Acute pancreatitis and liver injury associated with amoxicillin-clavulanic therapy. Rev Esp Enferm Dig. 1995; 87: 597–600. PMID: 7577112

58. De Gennes JL, Dairou F, Surbled-Delas B. [Demonstration of the role of cholelithiasis in the onset of acute pancreatitis occurring during clofibrate (or its analog) treatment of atherogenic hyperlipemia]. Ann Med Interne (Paris). 1978; 129: 435–439. PMID: 686580

59. Ben-Ami H, Pollack S, Nagachandran P, Lashevsky I, Yarnitsky D, Edoute Y. Reversible pancreatitis, hepatitis, and peripheral polyneuropathy associated with parenteral gold therapy. J Rheumatol. 1999; 26: 2049–2050. PMID: 10493691

60. Diaz J, Davalos M, Roman R, Bustios C, Zumaeta E. [Hepatotoxicity and pancreatitis associated with gold salts: case report]. Rev Gastroenterol Peru Organo Of Soc Gastroenterol Peru. 2004; 24: 353–356.

61. Eisemann AD, Becker NJ, Miner PJ, Fleming J. Pancreatitis and gold treatment of rheumatoid arthritis. Ann Intern Med. 1989; 111: 860–861.

62. Jain N, Savani M, Agarwal M, Sands CW. Albiglutide-induced pancreatitis. Ther Adv Drug Saf. 2016; 7: 236–238. https://doi.org/10.1177/2042098616667352 PMID: 27904741

63. Anderson JR, Johnston GW, Kennedy TL. Drug-associated recurrent pancreatitis. Dig Surg. 1985; 2: 24–26.

64. Caldarola V, Hassett JM, Hall AH, Bronstein AB, Kulig KW, Rumack BH. Hemorrhagic pancreatitis associated with acetaminophen overdose. Am J Gastroenterol. 1986; 81: 579–582. PMID: 3717123

65. Cavanaugh Z, Naut ER. Acetaminophen-induced acute pancreatic pseudocyst: first case report. Conn Med. 2014; 78: 37–39. PMID: 24600780

66. Coward RA. Paracetamol-induced acute pancreatitis. Br Med J. 1977; 1: 1086.

67. Fernandes R. Acute pancreatitis following paracetamol overdose. BMJ Case Rep. 2009; 2009. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pream&NEWS=N&AN=22096469

68. Gilmore IT, Tourvas E. Paracetamol-induced acute pancreatitis. Br Med J. 1977; 1: 753–754. https://doi.org/10.1136/bmj.1.6063.753 PMID: 851712

69. Igarashi H, Ito T, Yoshinaga M, Oono T, Sakai H, Takayanagi R. Acetaminophen-induced acute pancreatitis. A case report. JOP J Pancreas. 2009; 10: 550–553.

70. Mofenson HC, Caraccio TR, Nawaz H, Steckler G. Acetaminophen induced pancreatitis. J Toxicol Toxicol. 1991; 29: 223–230.

71. Lee WC, Wu MJ, Cheng CH, Chen CH, Wen MC, Chen HC, et al. Acute pancreatitis following antilymphocyte globulin therapy in a renal transplant recipient. Clin Nephrol. 2006; 65: 144–146. https://doi.org/10.5414/cnp65144 PMID: 16509467

72. Mahdi AS, Molai M, Chandwani J, Khalili HA, Ibrahim H, Pandak N, et al. Late onset acute pancreatitis in P. falciparum malaria—An adverse reaction to intravenous artemesunate? IDCases. 2018; 12: 124–126. https://doi.org/10.1016/j.idcr.2018.04.010 PMID: 29942768

73. Ayoob WA, Kumar AA, Naguib HS, Taylor HC. Exenatide-induced acute pancreatitis. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2010; 16: 80–83.

74. Denker PS, Dimarco PE. Exenatide (Exendin-4)-induced pancreatitis: A case report [13]. Diabetes Care. 2006; 29: 471.

75. Tripathy NR, Basha S, Jain R, Shetty S, Ramachandran A. Exenatide and acute pancreatitis. J Assoc Physicians India. 2008; 56: 987–988. PMID: 19322980

76. Ikeuchi K, Okuma Y, Tabata T. Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report. Lung Cancer. 2016; 99: 148–150. https://doi.org/10.1016/j.lungcan.2016.07.001 PMID: 27569331

77. Jiang R, Xu L, Huang Y, Fang C, Guo H, Li S, et al. Anti-PD-1 Drug (Nivolumab) May Induce Acute and Life-Threatening Pancreatitis in Lung Cancer Patient: A Case Report. Pancreas. 2018; 47: e53–e54. https://doi.org/10.1097/MPA.0000000000001107 PMID: 30113432
78. Abou Chacra L, Ghosn M, Ghayad E, Honein K. A case of pancreatitis associated with all-trans-retinoic acid therapy in acute promyelocytic leukemia. Hematol J Off J Eur Haematol Assoc. 2001; 2: 406–407.

79. Teng HW, Bai LY, Chao TC, Wang WS, Chen PM. Acute pancreatitis during all-trans-retinoic acid treatment for acute promyelocytic leukemia in a patient without overt hypertriglyceridemia. Jpn J Clin Oncol. 2005; 35: 94–96. https://doi.org/10.1093/jjco/hyi027 PMID: 15709095

80. Yutsudo Y, Imoto S, Ozuru R, Kajimoto K, Itoi H, Koizumi T, et al. Acute pancreatitis after all-trans retinoic acid therapy [1]. Ann Hematol. 1997; 74: 295–296. https://doi.org/10.1007/s002770050304 PMID: 9236517

81. Benavente Fernandez A, Barakat Shrem O, Ibanez Godoy I, Fernandez Perez MJ, Bolivar Raya MA. [Carbamazepine—induced pancreatitis]. An Med Interna Madr Spain 1984. 2004; 21: 199–200.

82. Forte A, Gallinaro L, Montesano G, Turano R, Bertagni A, Illuminati G. A possible case of carbamazepine induced pancreatitis. Riv Eur Sci Mediche E Farmacol Eur Rev Med Pharmacol Sci Rev Eur Pour Sci Medicales Pharmacol. 1996; 18: 187–189.

83. Javaloyas M, Casasin T. Acute pancreatitis by carbamazepine in an AIDS patient [1]. Med Clin (Barc). 1998; 110: 437.

84. Laczek JT, Shrestha M, Kortan ND, Lake JM. Carbamazepine-induced pancreatitis with positive rechallenge. J Clin Gastroenterol. 2010; 44: 153–154. https://doi.org/10.1097/MCG.0b013e3181aaaee53 PMID: 19636258

85. Storer A. A 54-year-old woman with a rare case of drug-induced pancreatitis. Adv Emerg Nurs J. 2011; 33: 23–28. https://doi.org/10.1097/TEN.0b013e318209c57e PMID: 21317695

86. Belache G, Ley G, Slama JL. [Acute pancreatitis associated with atorvastatin therapy]. Gastroenterol Clin Biol. 2000; 24: 471–472. PMID: 10844297

87. Deshpande PR, Khera K, Thunga G, Hande M, Gouda STG, Nagappa AN. Atorvastatin-induced acute pancreatitis. J Pharmacol Pharmacother. 2011; 2: 40–42. https://doi.org/10.4103/0976-500X.77114 PMID: 21701646

88. Prajapati S, Shah S, Desai C, Desai M, Dikshit RK. Atorvastatin-induced pancreatitis. Indian J Pharmacol. 2010; 42: 324–325. https://doi.org/10.1016/j.ijpharm.2010.02.001 PMID: 21066629

89. Flynn WJ, Freeman PG, Wickboldt LG. Pancreatitis associated with isotretinoin-induced hypertriglyceridemia. Ann Intern Med. 1987; 107: 63. https://doi.org/10.7326/0003-4819-107-1-63 PMID: 3035979

90. Jamshidi M, Obermeyer RJ, Govindaraj S, Garcia A, Ghani A. Acute pancreatitis secondary to isotretinoin-induced hyperlipidemia. J Okla State Med Assoc. 2002; 95: 79–80. PMID: 11845676

91. McCarter TL, Chen YK. Marked hyperlipidemia and pancreatitis associated with isotretinoin therapy. Am J Gastroenterol. 1992; 87: 1855–1858. PMID: 1449157

92. Alberti-Flore JJ. Pancreatitis associated with ondansetron [2]. J Natl Cancer Inst. 1995; 87: 689–690. https://doi.org/10.1093/jnci/87.9.689-a PMID: 7752274

93. Granados LM, Ballester F, Suarez F, Sanchez-Pena J, Navas E. [Acute postoperative pancreatitis, is it associated with the use of ondansetron?] Rev Esp Anestesiol Reanim. 1997; 44: 87.

94. Sebastian Domingo JJ, Simon Marco MA, Uribarrena Echebarria R. Hepatic and pancreatic injury associated with amineptine therapy. J Clin Gastroenterol. 1994; 18: 168–169. https://doi.org/10.1097/00004836-199403000-00023 PMID: 8189020

95. Aissaoui M, Mounedji N, Mathelier-Fusade P, Leynadier F. [Pancreatitis caused by azathioprine: immuno-allergy?]. Presse Medicale Paris Fr 1983. 1996; 25: 1650.

96. Alexander S, Dowling D. Azathioprine pancreatitis in inflammatory bowel disease and successful subsequent treatment with mercaptopurine. Intern Med J. 2005; 35: 570–571. https://doi.org/10.1111/j.1445-5994.2005.00881.x PMID: 16105163

97. Echarri A, Borda F, Jimenez FJ, Arin A, Martin-Granizo I, Aznarez R. [Acute pancreatitis caused by azathioprine in patient with Crohn disease]. Rev Espanola Enfermedades Dig Organo Of Soc Espanola Patol Dig. 1996; 88: 645–646.

98. Fernandez Lison LC, Perez Puente P, Martin Cillero MT, Garrido Amegieiras MR. [Acute secondary pancreatitis to azathioprine versus autoimmune pancreatitis in a patient with ulcerative colitis]. Farm Hosp Organo Of Expresion Cient Soc Espanola Farm Hosp. 2010; 34: 310–312.

99. Gallego-Gutierrez S, Navas-Lopez VM, Kolorz M, Bartosova L, Lukac K, Luque-Perez S, et al. Successful Mercaptopurine Usage despite Azathioprine-Induced Pancreatitis in Paediatric Crohn’s Disease. J Crohns Colitis. 2015; 9: 676–679. https://doi.org/10.1093/ecco-jcc/jv086 PMID: 25968582
100. Guillaume P, Grandjean E, Male PJ. Azathioprine-associated acute pancreatitis in the course of chronic active hepatitis. Dig Dis Sci. 1984; 29: 78–79. https://doi.org/10.1007/bf01296866 PMID: 6692736

101. Herskowitz LJ, Olansky S, Lang PG. Acute pancreatitis associated with long-term azathioprine therapy. Occurrence in a patient with systemic lupus erythematosus. Arch Dermatol. 1979; 115: 179. PMID: 426524

102. Isenberg JN. Pancreatitis, amylase clearance, and azathioprine. J Pediatr. 1978; 93: 1043–1044. https://doi.org/10.1016/s0022-3476(78)81256-6 PMID: 722424

103. Lai SW, Wang YC, Wang CH, Huang TY. Acute pancreatitis and erythema nodosum associated with azathioprine. QJM Mon J Assoc Physicians. 2012; 105: 363–364.

104. Ledder OD, Lemberg DA, Ooi CY, Day AS. Are thiopurines always contraindicated after thiopurine-induced pancreatitis in inflammatory bowel disease? J Pediatr Gastroenterol Nutr. 2013; 57: 583–586. https://doi.org/10.1097/MPG.0b013e31829f16fc PMID: 23783022

105. Paloyan D, Levin B, Simonowitz D. Azathioprine-associated acute pancreatitis. Am J Dig Dis. 1977; 22: 839–840. https://doi.org/10.1007/bf01694518 PMID: 900102

106. Roblin X, Becot F, Jacquot JM, Nairi A, Abinader J, Monnet D. [Azathioprine-induced acute pancreatitis]. Ann Gastroenterol Hepatol (Paris). 1990; 26: 233. PMID: 2256671

107. Siwach V, Bansal V, Kumar A, Rao Ch U, Sharma A, Minz M. Post-renal transplant azathioprine-induced pancreatitis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc—Eur Ren Assoc. 1999; 14: 2495–2498.

108. Tragnone A, Bazzocchi G, Aversa G, Pecorelli MG, Elmi G, Venerato S, et al. Acute pancreatitis after azathioprine treatment for ulcerative colitis. Ital J Gastroenterol. 1996; 28: 102–104. PMID: 8782004

109. Venkatesh PGK, Navaneethan U. Azathioprine-induced pancreatitis in a patient with co-existing autoimmune pancreatitis and hepatitis. J Pancreas. 2011; 12: 250–254.

110. Basturk A, Yilmaz A, Keceli M, Artan R. Infliximab treatment in a paediatric patient with ulcerative colitis, who developed acute pancreatitis due to azathioprine during follow-up. Gastroenterol Rev. 2017; 3: 235–237. https://doi.org/10.5114/pg.2017.70479 PMID: 29123588

111. Lopez Centeno B, Perez Encinas M, Sanz Marquez S. ACUTE SECONDARY PANCREATITIS TO AZATHIOPRINE IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS. 2013; 15: 3.

112. Mann S, Thillainayagam A. Is ciprofloxacin a new cause of acute pancreatitis? [1]. J Clin Gastroenterol. 2000; 31: 336. https://doi.org/10.1097/00004836-200012000-00014 PMID: 11129278

113. Kitamura Y, Yoshii H, Nishimoto K, Shinchi Y, Tokonabe S, Takao M, et al. A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma. Keio J Med. 2015; 64: 62–64. https://doi.org/10.2302/kjm.2015-0001-CP PMID: 26727578

114. Almeida DM, Jean MR, Chystsiakov A, Monahan E, Oliveira SB, Monteiro IM. Levetiracetam-associated acute pancreatitis in an adolescent with autism: a case report. Pancreas. 2013; 42: 177–178. https://doi.org/10.1097/MPA.0b013e318258dc91 PMID: 23549134

115. Azer AJ, Aune P. Acute pancreatitis and elevated liver transaminases after rapid titration of oral levetiracetam. J Clin Neurosci Off J Neurosurg Soc Australas. 2014; 21: 1053–1054.

116. Im MS, Ahn HS, Cho HJ, Kim KB, Lee HY. Diabetic ketoacidosis associated with acute pancreatitis in a heart transplant recipient treated with tacrolimus. Exp Clin Transplant Off J Middle East Soc Organ Transplant. 2013; 11: 72–74.

117. Nieto Y, Russ P, Everson G, Bearman SL, Cagnoni PJ, Jones RB, et al. Acute pancreatitis during immunosuppression with tacrolimus following an allogeneic umbilical cord blood transplantation. Bone Marrow Transplant. 2000; 26: 109–111. https://doi.org/10.1038/sj.bmt.1702471 PMID: 10918414

118. Muchnick JS, Mehta JL. Angiotensin-converting enzyme inhibitor-induced pancreatitis. Clin Cardiol. 1999; 22: 50–51. https://doi.org/10.1002/clc.4960220117 PMID: 9929757

119. Poldermans D, van Blankenstein M. Pancreatitis induced by disodium azosaldisalicylate. Am J Gastroenterol. 1988; 83: 578–580. PMID: 2452567

120. Garau P, Orenstein SR, Neigt DA, Kocoshis SA. Pancreatitis associated with osalazine and sulfasalazine in children with ulcerative colitis. J Pediatr Gastroenterol Nutr. 1994; 18: 481–485. https://doi.org/10.1097/00005176-199405000-00015 PMID: 7520936
123. Arbel Y, Weinstein D, Yogev R, Halevy A. Acute pancreatitis following clomiphene citrate treatment: Case report and review of the literature. Int J Surg. 2008; 6: 483–484. https://doi.org/10.1016/j.ijsu.2006.06.024 PMID: 19059153

124. Castro MR, Nguyen TT, O’Brien T. Clomiphene-induced severe hypertriglyceridemia and pancreatitis. Mayo Clin Proc. 1999; 74: 1125–1128. https://doi.org/10.4065/74.11.1125 PMID: 10560601

125. Bilal JM, Carvalho-Filho RJ, Mota CFMGP, Fucuta P da S, Ferraz MLCG. Acute pancreatitis associated with boceprevir: a case report. Braz J Infect Dis Off Publ Braz Soc Infect Dis. 2014; 18: 454–456.

126. Sue M, Yoshishara A, Kuboki K, Hiroi N, Yoshino G. A case of severe acute necrotizing pancreatitis after administration of sitagliptin. Clin Med InsightsCase Rep. 2013; 6: 23–27.

127. Kocak MZ, Aktas G, Erkus E, Duman TT, Atak BM, Sahin D, et al. A Case of Sitagliptin-Induced Mild Acute Pancreatitis. J Coll Physicians Surg—Pak JCPSP. 2018; 28: 334. https://doi.org/10.29271/jcpsp.2018.04.334 PMID: 29615184

128. Yen JM, Tan LF, Sze YL. Sitagliptin related pancreatitis in the elderly: A rare but serious complication. Eur Geriatr Med. 2017; 8: 377–378. https://doi.org/10.1016/j.eurger.2017.07.006

129. Urru SAM, Mariotti E, Carta P, Massidda S, Marcias M, Murru R, et al. Acute pancreatitis following brentuximab vedotin therapy for refractory Hodgkin lymphoma: a case report. Drugs R D. 2014; 14: 9–11. https://doi.org/10.1007/s40268-014-0036-x PMID: 24493297

130. Gang N, Langevitz P, Livneh A. Relapsing acute pancreatitis induced by re-exposure to the cholesterol lowering agent bezafibrate. Am J Gastroenterol. 1999; 94: 3626–3628. https://doi.org/10.1111/j.1572-0241.1999.01621.x PMID: 10606331

131. Francobandiera G, Rondalli G, Telattin P. Acute pancreatitis associated with clothiapine use. Hum Psychopharmacol. 1999; 14: 211–212.

132. Talamo G, Sivik J, Pandey MK, Mir MA. Bortezomib-induced acute pancreatitis: Case report and review of the literature. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract. 2016; 22: 332–334.

133. Wang HH, Tsui J, Wang XY, Liu SS, Li J. Bortezomib-induced acute pancreatitis in a patient with multiple myeloma. Leuk Lymphoma. 2014; 55: 1404–1405. https://doi.org/10.3109/10428194.2013.831850 PMID: 23927397

134. Nykamp D, Kraus EJ. Antacid-induced acute pancreatitis. Consult Pharm J Am Soc Consult Pharm. 2013; 28: 247–251.

135. Iliopoulou A, Giannakopoulos G, Pagoy H, Christos T, Theodore S. Acute pancreatitis due to captopril treatment. Dig Dis Sci. 2001; 46: 1882–1883. https://doi.org/10.1023/a:1010674812573 PMID: 11575439

136. Jeandidier N, Klewansky M, Pinget M. Captopril-induced acute pancreatitis. Diabetes Care. 1995; 18: 410–411. https://doi.org/10.2337/diacare.18.3.410 PMID: 7555489

137. Bayard JMF, Descamps OS, Evrard S, Dumonceau JM, Servais L, Zingir Z, et al. Case report: acute pancreatitis induced by Clozapine. Acta Gastro-Enterol Belg. 2005; 68: 92–94.

138. Cerulli TR. Clozapine-associated pancreatitis. Harv Rev Psychiatry. 1999; 7: 61–63. PMID: 10439307

139. Chengappa KN, Pelucio M, Baker RW, Cole D. Recurrent pancreatitis on clozapine re-challenge. J Psychopharmacol (Oxf). 1995; 9: 381–382.

140. Gatto EM. Clozapine and pancreatitis. Clin Neuropharmacol. 1998; 21: 203. PMID: 9617515

141. Huang YJ, Lane HY, Liao CH, Huang CC. Recurrent pancreatitis without eosinophilia on clozapine rechallenge. Prog Neuropsychopharmacol Biol Psychiatry. 2009; 33: 1561–1562. https://doi.org/10.1016/j.pnpbp.2009.08.019 PMID: 19735691

142. Martin A. Acute pancreatitis associated with clozapine use [12]. Am J Psychiatry. 1992; 149: 714.

143. Raja M, Azzoni A. A case of clozapine-associated pancreatitis. Open Neuropsychopharmacol J. 2011; 4: 5–7.

144. Wehmeier PM, Heiser P, Remschmidt H. Pancreatitis followed by pericardial effusion in an adolescent treated with clozapine. J Clin Psychopharmacol. 2003; 23: 102–103. https://doi.org/10.1097/00004714-200302000-00017 PMID: 12544384

145. Srivalli N, Thongprayoon C, Cheungasitporn W, Ungrasert P. Acute pancreatitis in the use of canagliflozin: A rare side-effect of the novel therapy for type 2 diabetes mellitus. J Basic Clin Pharm. 2015; 6: 101–102. https://doi.org/10.4036/0976-0105.160753 PMID: 26229348

146. Patel KM, Pikas E, George T. Drug-Induced Necrotizing Pancreatitis With a Focus on Canagliflozin. Am J Ther. 2017; 24; e496. https://doi.org/10.1097/MJT.0000000000000561 PMID: 28639664
148. Chan HY, Ng CM, Tiu SC, Chan AOK, Shek CC. Hypertriglyceridaemia-induced pancreatitis: A contributory role of capecitabine? Hong Kong Med J. 2012; 18: 526–529. PMID: 23223655

149. Chng CL, Kek PC, Khoo DHC. Carbimazole-induced acute pancreatitis and cholestatic hepatitis. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2011; 17: 960–961.

150. Marazuela M, Sanchez de Paco G, Jimenez I, Carraro R, Fernandez-Herrera J, Pajares JM, et al. Acute pancreatitis, hepatic cholestasis, and erythema nodosum induced by carbimazole treatment for Graves’ disease. Endocr J. 2002; 49: 315–318. https://doi.org/10.1507/endocrj.49.315 PMID: 12201214

151. Altman AJ, Dinndorf P, Quinn JJ. Acute pancreatitis in association with cytosine arabinoside therapy. Cancer. 1982; 49: 1384–1386. https://doi.org/10.1002/1097-0142(19820401)49:7<1384::AID-CNCR2820490714>3.0.co;2-6 PMID: 6949626

152. McBride CE, Yavorski RT, Moses FM, Robson ME, Solimando Jr, Byrd JC. Acute pancreatitis associated with continuous infusion cytarabine therapy. Cancer. 1996; 77: 2588–2591. https://doi.org/10.1002/(SICI)1097-0142(19960615)77:12<2588::AID-CNCR24>3.0.CO;2-N PMID: 8640710

153. Siemers RF, Friedenberg WR, Norfleet RG. High-dose cytosine arabinoside-associated pancreatitis. Cancer. 1985; 56: 1940–1942. https://doi.org/10.1002/1097-0142(19851015)56:8<1940::AID-CNCR2820560808>3.0.co;2-n PMID: 2411382

154. Gill CJ, Jennings AE, Newton JB, Schwartz DE. Fatal acute pancreatitis in a patient chronically treated with candesartan. J Pharm Technol. 2005; 21: 79–82.

155. Prigigine T, Futeral B, Kraytman M. Acute hemorrhagic pancreatitis associated with chlorthalidone therapy. Acta Clin Belg. 1978; 33: 272.

156. Arnold F, Doyle PJ, Bell G. Acute pancreatitis in a patient treated with cimetidine. Lancet Lond Engl. 1978; 1: 382–383.

157. Hainaut P, Schapira M, Mugabo P, Cerulus G, Coche E. Cimetidine-induced acute pancreatitis. Rev Med Interne. 1987; 8: 516–518. https://doi.org/10.1016/s0248-8663(87)80204-7 PMID: 3445034

158. Nott DM, de Sousa BA. Suspected cimetidine-induced acute pancreatitis. Br J Clin Pract. 1989; 43: 264–265. PMID: 2480803

159. Seo JH, Lee DY, Hong CW, Lee IH, Ahn KS, Kang GW. Severe lactic acidosis and acute pancreatitis associated with cimetidine in a patient with type 2 diabetes mellitus taking metformin. Intern Med Tokyo Jpn. 2013; 52: 2245–2248.

160. Wilkinson ML, O’Driscoll R, Kieman TJ. Cimetidine and pancreatitis. Lancet Lond Engl. 1981; 1: 610–611.

161. Levine RA, McGuire RF. Corticosteroid-induced pancreatitis: a case report demonstrating recurrence with rechallenge. Am J Gastroenterol. 1988; 83: 1161–1164. PMID: 3421228

162. Baciewicz AM, King TJ, Sokos DR. Acute pancreatitis associated with celecoxib [12]. Ann Intern Med. 2000; 132: 680.

163. Godino J, Butani RC, Wong PWK, Murphy FT. Acute drug-induced pancreatitis associated with celecoxib [5]. J Clin Rheumatol. 1999; 5: 305–307.

164. Mennecier D, Ceppa F, Sinayoko L, Corberand D, Harnois F, Thiolet C, et al. [Acute pancreatitis after treatment by celecoxib]. Gastroenterol Clin Biol. 2007; 31: 668–669. https://doi.org/10.1016/s0399-8320(07)91915-6 PMID: 17925765

165. Nind G, Selby W. Acute pancreatitis: A rare complication of celecoxib [3]. Intern Med J. 2002; 32: 624–625. https://doi.org/10.1046/j.1445-5994.2002.00298.x PMID: 12512760

166. Hasting P, Buckley MJ, Peten EP, Demuth N, Dumas R, Demarquay JF, et al. A new source of drug-induced acute pancreatitis: codeine. Am J Gastroenterol. 2000; 95: 3295–3298. https://doi.org/10.1111/j.1572-0241.2000.03213.x PMID: 11095359

167. Moreno Escobosa MC, Amat Lopez J, Cruz Granados S, Moya Quesada MC. Pancreatitis due to codeine. Allergol Immunopathol (Madr). 2005; 33: 175–177.

168. Allauochiche B, Duffo F, Cotte L, Mathon L, Chassard D. Acute pancreatitis with severe lactic acidosis in an HIV-infected patient on didanosine therapy. J Antimicrob Chemother. 1999; 44: 137–138. https://doi.org/10.1093/jac/44.1.137 PMID: 10459826

169. Bouvet E, Casalino E, Prevost MH, Vachon F. Fatal case of 2’,3’-dideoxyinosine-associated pancreatitis. Lancet Lond Engl. 1990; 336: 1515.

170. Cina SJ, Conradi SE. Acute pancreatitis in a prisoner with AIDS. Bugs or drugs? Am J Forensic Med Pathol. 1994; 15: 28–31. https://doi.org/10.1097/00000433-199403000-00007 PMID: 8166111

171. Levin TL, Berdon WE, Tang HB, Haller JO. Dideoxyinosine-induced pancreatitis in human immunodeficiency virus-infected children. Pediatr Radiol. 1997; 27: 189–191. https://doi.org/10.1007/s002470050099 PMID: 9028860
172. Maxson CJ, Greenfield SM, Turner JL. Acute pancreatitis as a common complication of 2',3'-dideoxyinosine therapy in the acquired immunodeficiency syndrome. Am J Gastroenterol. 1992; 87: 708–713. PMID: 1590305

173. Avraam C, Siomos K, Armenaka MC, Sion ML. Clarithromycin associated acute pancreatitis. Ann Gastroenterol. 2007; 20: 35–37.

174. Gonzalez Carro P, Perez Roldan F, Legaz Huidobro ML, Moralde de Acuna M, Nieto Garcia JC. Acute pancreatitis and modified-release clarithromycin. Ann Pharmacother. 2004; 38: 508–509.

175. Koufakis T, Gabranis I, Ntasis K, Karangelis D, Batalla S, Paschala N, et al. Acute pancreatitis due to clarithromycin therapy: A rare adverse effect of a common drug. Eur J Intern Med. 2013; 24: e77. https://doi.org/10.1016/j.ejim.2013.01.007

176. Liviu L, Yair L, Yehuda S. Pancreatitis induced by clarithromycin. Ann Intern Med. 1996; 125: 701.

177. Schouwenberg BJW, Deinum J. Acute pancreatitis after a course of clarithromycin. Neth J Med. 2003; 61: 266–267. PMID: 14567525

178. Bunin N, Meyer WH, Christensen M, Pratt CB. Pancreatitis following cisplatin: a case report. Cancer Treat Rep. 1985; 69: 236–237. PMID: 3855700

179. Das AK, Jawed Q. Drug-induced acute pancreatitis: a rare manifestation of an incomplete “dapsoine syndrome.” Indian J Pharmacol. 2014; 46: 455–457. https://doi.org/10.4103/0253-7613.135967 PMID: 25697293

180. Jha SH, Reddy JA, Dave JK. Dapsone-induced acute pancreatitis. Ann Pharmacother. 2003; 37: 1438–1440. https://doi.org/10.1345/aph.1C482 PMID: 14519046

181. Navarro-Mingorance A, Castellanos-Alcarria AJ, Ibanez-Mico S, Cervantes-Pardo A, Sanchez-Pedreno P. Dapsone-induced isolated acute pancreatitis in a child with linear IgA dermatitis. Indian J Pediatr. 2014; 81: 735–736. https://doi.org/10.1007/s12098-013-1222-5 PMID: 24037496

182. McCormick PA, O’Donoghue D, Brennan N. Diphenoxylate and pancreatitis. Lancet Lond Engl. 1985; 1: 752.

183. Balasch J, Martinez-Roman S, Carreras J, Vanrell JA. Acute pancreatitis associated with danazol treatment for endometriosis. Hum Reprod Oxf Engl. 1994; 9: 1163–1165.

184. Roberge RJ, Martin TG, Hodgman M, Benitez JG. Acute chemical pancreatitis associated with a tricyclic antidepressant (clomipramine) overdose. J Toxicol Toxicol. 1994; 32: 425–429.

185. Anton Aranda E, Altuna Basurto E. [Acute pancreatitis and erythromycin]. Med Clin (Barc). 1991; 96: 638.

186. Berger TM, Cook WJ, O’Marcaigh AS, Zimmerman D. Acute pancreatitis in a 12-year-old girl after an erythromycin overdose. Pediatrics. 1992; 90: 624–626. PMID: 1408521

187. Gonzalez Carro P, Ribes F, Garcia MJ. Acute pancreatitis associated with erythromycin [2]. Rev Esp Enferm Dig. 1995; 87: 757–758. PMID: 8519548

188. Fang CC, Wang HP, Lin JT. Erythromycin-induced acute pancreatitis. J Toxicol Toxicol. 1996; 34: 93–95.

189. Guerrero Igea FJ, Lepe Jimenez JA, Garrido Serrano A, Palomo Gil S. [Acute pancreatitis caused by erythromycin]. An Med Interna Madr Spain 2001; 18: 400.

190. Gumaste VV. Erythromycin-induced pancreatitis. Am J Med. 1989; 86: 725. https://doi.org/10.1016/0002-9343(89)90456-7 PMID: 2729328

191. Hawksworth CR. Acute pancreatitis associated with infusion of erythromycin lactobionate. BMJ. 1989; 298: 190.

192. Pascual Velasco F, Goicoechea Ibarra L, Bichara Antanios G. [Acute pancreatitis induced by erythromycin: a new case]. Med Clin (Barc). 1991; 97: 473–474.

193. Surinach JM, Alegre J, Fernandez de Sevilla T, Queralt M. [Acute pancreatitis from erythromycin]. Rev Clin Esp. 1993; 192: 458.

194. Teillet L, Chaussade S, Mory B, Roche H, Couturier D, Guerre J. [Drug-induced acute pancreatitis following intravenous erythromycin antibiotic therapy]. Gastroenterol Clin Biol. 1991; 15: 265–266. PMID: 2044892

195. Tenenbein MS, Tenenbein M. Acute pancreatitis due to erythromycin overdose. Pediatr Emerg Care. 2005; 21: 675–676. https://doi.org/10.1097/01pec.0000181419.49106.ec PMID: 16215473

196. Wong PW, Dillard TA, Kroenke K. Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy. South Med J. 1998; 91: 202–205. https://doi.org/10.1097/00007611-199802000-00015 PMID: 9496876

197. Chhaparia A, Hammami MB, Vareedayah A, Schroeder K. Eluxadoline-Associated Pancreatitis in a Post-Cholecystectomy Patient: A Case Report. Del Med J. 2017; 89; 90–92. PMID: 29894043
198. Khetpal N, Yadav L, Khalid S, Kumar R. Eluxadoline-induced Recurrent Pancreatitis in a Young Female without a Gallbladder: A Case Report and Literature Review. Cureus. 2018; 10: e3747. https://doi.org/10.7759/cureus.3747 PMID: 30820368

199. Bories JM, Bauret P, Larrey D, Michel H. [Acute pancreatitis and dexfenfluramine (Isomeride): a propos of a case]. Gastroenterol Clin Biol. 1992; 16: 817–818. PMID: 1478418

200. Amery A, Vandenbroucke J, Desbuquoit JL, De GJ. Pancreatitis during clonidine treatment. TGAS-TRO-ENT. 1973; 16: 179–185.

201. Tysk C, Al-Eryani AY, Shawabkeh AA. Acute pancreatitis induced by fluvastatin therapy. J Clin Gastroenterol. 2002; 35: 406–408. https://doi.org/10.1097/00004836-200211000-00010 PMID: 12394230

202. Carnovale A, Esposito P, Bassano P, Russo L, Uomo G. Enalapril-induced acute recurrent pancreatitis. Dig Liver Dis. 2003; 35: 55–57. https://doi.org/10.1016/s1590-8658(02)0012-9 PMID: 12725609

203. Madsen JS, Jacobsen IA. Angiotensin converting enzyme inhibitor therapy and acute pancreatitis. Blood Press. 1995; 4: 369–371. https://doi.org/10.3109/0837059509077623 PMID: 8746605

204. Maringhini A, Termini A, Patti R, Ciambella M, Biffarella P, Pagliaro L. Enalapril-associated acute pancreatitis: recurrence after rechallenge. Am J Gastroenterol. 1997; 92: 166–167. PMID: 8995963

205. Martin T, Taupignon A, Graf E, Perrin D. [Pancreatitis and hepatitis in a patient treated with enalapril maleate. A case report]. Therapie. 1989; 44: 449–450. PMID: 2560267

206. Moreno Sanchez-Canete A, Bernardino de la Serna JI, Garcia Puig J, Gil Agudo A. [Acute pancreatitis associated with ACE inhibitors]. Aten Primaria. 1998; 22: 260–261. PMID: 9803579

207. Gonzalez Ramallo VJ, Muino Miguez A, Torres Segovia FJ. Nectrotizing pancreatitis and enalapril. Eur J Med. 1992; 1: 123. PMID: 1342370

208. Roush MK, McNutt RA, Gray TF. The adverse effect dilemma: Quest for accessible information. Ann Pharmacother. 2006; 40: 128–134. https://doi.org/10.1345/aph.1G314 PMID: 16352777

209. Choi JW, Lee JS, Paik WH, Song TJ, Kim JW, Bae WK, et al. Acute pancreatitis associated with peglated interferon-alpha-2a therapy in chronic hepatitis C. Clin Mol Hepatol. 2016; 22: 168–171. https://doi.org/10.3350/cmh.2016.22.1.168 PMID: 27044768

210. Kovacic S, Robinic S, Nemrava J, Gospovic K, Seferovic Saric M, Luetic K. Acute pancreatitis in two patients with Parkinson’s disease. Schumacher U, editor. Cogent Med. 2017; 4. https://doi.org/10.1080/2331205X.2017.1312802

211. Pedrol E, Martos JA, Plaza V, Celis R,Montserrat JM. [Acute pancreatitis caused by demeclocycline]. Rev Clin Esp. 1989; 184: 392–393. PMID: 2505341

212. Call T, Malarkey WB, Thomas FB. Acute pancreatitis secondary to furosemide with associated hyperlipidemia. Am J Dig Dis. 1977; 22: 835–838. https://doi.org/10.1016/0002-9345(77)90374-3 PMID: 900101

213. Chao CT, Chao JY. Case report: furosemide and pancreatitis: Importance of dose and latency period before reaction. Can Fam Physician Med Fam Can. 2013; 59: 43–45.

214. Juang P, Page RL, Zolty R. Probable loop diuretic-induced pancreatitis in a sulfonamide-allergic patient. Ann Pharmacother. 2006; 40: 128–134. https://doi.org/10.1345/aph.1G314 PMID: 16352777

215. Stenvinkel P, Alvestrand A. Loop diuretic-induced pancreatitis with rechallenge in a patient with malignant hypertension and renal insufficiency. Acta Med Scand. 1988; 224: 89–91. https://doi.org/10.1111/j.0954-6820.1988.tb16743.x PMID: 2458013

216. Coschieri M, Dor DF, Andrieux G, Alessandra JP, Dulbecco P. [Acute pancreatitis and diethylstilbestrol (Distilben)]. Gastroenterol Clin Biol. 1994; 18: 1040–1041. PMID: 7705567

217. Lee YD, Lee ST. Acute pancreatitis and acute renal failure complicating oxalylamine sulfinate intoxication. Vet Hum Toxicol. 2002; 44: 165–166. PMID: 12046971

218. Cecchi E, Forte P, Cini E, Banchelli G, Fertito C, Mugelli A. Pancreatitis induced by pegylated interferon alfa-2b in a patient affected by chronic hepatitis C. Emerg Med Australas EMA. 2004; 16: 475–477. https://doi.org/10.1111/j.1742-6723.2004.00053.x PMID: 15937413

219. Choi JW, Lee JS, Paik WH, Song TJ, Kim JW, Bae WK, et al. Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C. Clin Mol Hepatol. 2016; 22: 168–171. https://doi.org/10.3350/cmh.2016.22.1.168 PMID: 27044768

220. Goldman KE, Marshall MK, Alessandrini E, Bernstein ML. Complications of alpha-interferon therapy for aggressive central giant cell lesion of the maxilla. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005; 100: 285–291. https://doi.org/10.1016/j.tripleo.2004.11.024 PMID: 16122854
223. Ozdogan O, Tahan V, Cincin A, Imeryuz N, Tozun N. Acute pancreatitis associated with the use of peginterferon [5]. Pancreas. 2007; 34: 485–487. https://doi.org/10.1097/MPA.0b013e318033af9 PMID: 17446854

224. Roguedas AM, Lonceint J, Sassolas B, de Saint Martin L, Guillot G. [Acute pancreatitis after high-dose interferon therapy in a patient with melanoma]. Presse Medicaire Paris Fr 1993. 2001; 30: 1105.

225. Sevenet F, Sevenet C, Capron D, Descombes P. Acute pancreatitis associated with interferon alpha therapy [2]. Gastroenterol Clin Biol. 1999; 23: 1256. PMID: 10651535

226. Sotomatsu M, Shimoda M, Ogawa C, Morikawa A. Acute pancreatitis associated with interferon-alpha therapy [2]. Gastroenterol Clin Biol. 1999; 23: 1256. PMID: 10651535

227. Tahan V, Tahan G, Dane F, Uraz S, Yardim M. Acute pancreatitis attributed to the use of pegylated interferon in a patient with chronic hepatitis C [3]. J Gastrointestin Liver Dis. 2007; 16: 224–225. PMID: 17592576

228. Tannir NM, Talpaz M, Ghazal H, Proothi S, Kantarjian HM. Acute pancreatitis associated with interferon alpha therapy for chronic myelogenous leukemia. Leuk Lymphoma. 2000; 39: 647–650. https://doi.org/10.1080/1042819009113396 PMID: 11342349

229. Vignon RK, Seddik H, Rouibaa F, En-Nouali H, Kabbaaj N, Benkirane A. Acute pancreatitis during pegylated interferon therapy in a patient with chronic hepatitis B. J Gastrointest Liver Dis JGLD. 2009; 18: 512.

230. Eland IA, Rasch MC, Sturkenboom MJ, Bekkerling FC, Brouwer JT, Delwaide J, et al. Acute pancreatitis attributed to the use of interferon alfa-2b. Gastroenterology. 2000; 119: 230–233. https://doi.org/10.1053/gast.2000.8528 PMID: 10889173

231. de Beaufort C, Beck P, Seligmann R, de Meirleir L, de Schepper J. Acute pancreatitis after growth hormone treatment: disease or treatment linked? Eur J Pediatr. 2006; 165: 652–653. https://doi.org/10.1007/s00431-006-0126-z PMID: 16691411

232. Malozowski S, Hung W, Scott DC, Stadel BV. Acute pancreatitis associated with growth hormone therapy for short stature [6]. N Engl J Med. 1995; 332: 401–402.

233. Sepulveda Vildosola AC, Lopez Aguilar E, Yanez Lopez P, Ramirez Colorado R, Escobar Padilla B, Madrazo De la Garza A. [Sodium diphenylhydantoin as a probable cause of pancreatitis]. Rev Gastroenterol Mex. 1999; 64: 186–189. PMID: 10851582

234. Martinez-Granados F, Navarro JN, Estrada JL, Martinez-Lazcano MT, Lluis-Casajana F, Ordoval-Baines JP. Ertapenem-induced acute pancreatitis in a surgical elderly patient. Pharm World Sci PWS. 2008; 30: 278–280. https://doi.org/10.1007/s11096-007-9178-z PMID: 18046618

235. Briongos-Figuero LS, Bachiller-Luque P, Pons-Renedo F, Eiros-Bouza JM. Isoniazid-induced acute pancreatitis [2]. Enferm Infecc Microbiol Clin. 2007; 25: 217–218.

236. Chan KL, Chan HS, Lui SF, Lai KN. Recurrent acute pancreatitis induced by isoniazid. Tuber Lung Dis Off J Int Union Tuberc Lung Dis. 1994; 75: 383–385.

237. Chow KM, Szeto CC, Leung CB, Li PKT. Recurrent acute pancreatitis induced by isoniazid. Tuber Lung Dis Off J Int Union Tuberc Lung Dis. 1994; 75: 383–385.

238. Izzedine H, Launay-Vacher V, Storne T, Deray G. Acute pancreatitis induced by isoniazid. Am J Gastroenterol. 2001; 96: 3208–3209.

239. Mendoza JL, Larrubia JR, Lana R, Espinos D, Diaz-Rubio M. [Acute pancreatitis induced by isoniazid, a casual association]. An Med Interna Madrid Spain 1984. 1998; 15: 588–590.

240. Rabassa AA, Trey G, Shukla U, Samo T, Anand BS. Isoniazid-induced acute pancreatitis. Ann Intern Med. 1994; 121: 433–434. https://doi.org/10.7326/0003-4819-121-6-199409150-00007 PMID: 8053617

241. Saleem AF, Arbab S, Naz FQ. Isoniazid induced acute pancreatitis in a young girl. J Coll Physicians Surg—Pak JCPSP. 2015; 25: 299–300. PMID: 25899200

242. Sanchez AJ, Boken DJ. Isoniazid-associated pancreatitis. Infect Med. 2004; 21: 622–623.

243. Stephenson I, Wiselka MJ, Qualie MJ. Acute pancreatitis induced by isoniazid in the treatment of tuberculosis. Am J Gastroenterol. 2001; 96: 2271–2272. https://doi.org/10.1111/j.1572-0241.2001.03984.x PMID: 11467674

244. Yi PH, Veltre DR, Kuttab JS, Rangan V, Norton L. Acute groove pancreatitis due to isoniazid. Neth J Med. 2013; 71: 104. PMID: 23462062

245. Rion RJ. Recurrent pancreatitis after treatment with hydrochlorothiazide. J Am Board Fam Pract. 1994; 7: 74–76. PMID: 7510925

246. Shafqet MA, Brown TV, Sharma R. Normal lipase drug-induced pancreatitis: A novel finding. Am J Emerg Med. 2015; 33: 476.
247. Luo H, Bhattacharya S, Mohammad S, Uhr E, Sen S, Mathew T, et al. Acute pancreatitis: possible association of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis. J Neurol. 2015; 262: 779–780. https://doi.org/10.1007/s00415-015-7649-z PMID: 25626723

248. Olson EL, Whang YE. Hypertriglyceridemia and pancreatitis associated with estramustine phosphate. Am J Clin Oncol Cancer Clin Trials. 2002; 25: 342–343.

249. Bekassy A, Wiebe T, Hochberg P. Erwinase-induced pancreatitis. Lancet Lond Engl. 1992; 340: 1552–1553.

250. Berrak SG, Canpolat C, Berik P, Kiyan G. Pancreatic pseudocyst following acute pancreatitis induced by L-asparaginase treatment. Int J Pediatr Hematol. 2001; 7: 413–416.

251. Bertolone SJ, Fuenfer MM, Groff DB, Patel CC. Delayed pancreatic pseudocyst formations. Long-term complication of L-asparaginase treatment. Cancer. 1982; 50: 2964–2966. https://doi.org/10.1002/1097-0193(19821215)50:12<2964::aid-cncr2820501244>3.0.co;2-9 PMID: 7139589

252. Chambon JP, Dupriez B, Danjou P, Provost M, Bauters F, Wurtz A, et al. [Acute necrotic pancreatitis secondary to asparaginase. Role of drug combinations—early diagnosis and treatment. Apropos of 2 cases]. J Chir (Paris). 1993; 130: 74–78.

253. Charan VD, Desai N, Singh AP, Choudhry VP. Diabetes mellitus and pancreatitis as a complication of L-asparaginase therapy. Indian Pediatr. 1993; 30: 809–810. PMID: 8132268

254. Chen CH, Lu MY, Lin KH, Lin DT, Pang SF, Jou ST. Ureteral obstruction caused by L-asparaginase-induced pancreatitis in a child with acute lymphoblastic leukemia. J Formos Med Assoc. 2001; 7: 413–416.

255. Cheung YF, Lee CW, Chan CF, Chan KL, Lau YL, Yeung CY. Somatostatin therapy in L-asparaginase-induced pancreatitis. Med Pediatr Oncol. 1994; 22: 421–424. https://doi.org/10.1002/mpeo.2950220614 PMID: 7908715

256. Garrington T, Bensard D, Ingram JD, Silliman CC. Successful management with octreotide of a child with L-asparaginase-induced hemorrhagic pancreatitis. Med Pediatr Oncol. 1998; 30: 380–384. PMID: 15216406

257. Greenstein R, Nogeire C, Ohnuma T, Greenstein A. Management of asparaginase-induced hemorhagic pancreatitis complicated by pseudocyst. Cancer. 1979; 43: 718–722. https://doi.org/10.1002/1097-0142(197902)43:2<718::aid-cncr2820430247>3.0.co;2-m PMID: 9403019

258. Koniver GA, Scott JE. Pancreatitis with pseudocyst: a complication of L-asparaginase therapy for leukemia. Del Med J. 1978; 50: 330–332. PMID: 668953

259. Murakawa M, Okamura T, Shibuya T, Harada M, Otsuka T, Niho Y. Use of a synthetic protease inhibitor for the treatment of L-asparaginase-induced acute pancreatitis complicated by disseminated intravascular coagulation. Ann Hematol. 1992; 64: 249–252. https://doi.org/10.1007/bf01793905 PMID: 1623061

260. Pecquenard L, Damay M, Naveau C, Lemarchand V, Dufay E, Berod T. [Delay ed acute pancreatitis after treatment with L-asparaginase. A case report]. Therapie. 1990; 45: 453–454.

261. Sadoff J, Hwang S, Rosenfeld D, Ettinger L, Spigland N. Surgical pancreatic complications induced by L-asparaginase. J Pediatr Surg. 1997; 32: 860–863. https://doi.org/10.1016/s0022-3468(97)90636-9 PMID: 9200086

262. Tan CL, Chiang SP, Wee KP. Acute haemorrhagic pancreatitis following L-asparaginase therapy in acute lymphoblastic leukaemia: a case report. Singapore Med J. 1974; 15: 278–282. PMID: 4533158

263. Top PC, Tissing WJE, Kuiper JW, Pieters R, van Eijck CHJ. L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage. Pediatr Blood Cancer. 2005; 44: 95–97. https://doi.org/10.1002/pbc.20187 PMID: 15368548

264. Wu F, Ou L, Tan Y, Zhang Y, Hu C. L-asparaginase-induced severe acute pancreatitis in an adult with extranodal natural killer/T-cell lymphoma, nasal type: A case report and review of the literature. Oncol Lett. 2014; 7: 1305–1307. https://doi.org/10.3892/ol.2014.1871 PMID: 24944714

265. Yu CH, Lin KH, Lin DT, Chen RL, Horng YC, Chang MH. L-asparaginase-related pancreatic pseudocyst: report of a case. J Formos Med Assoc Taiwan Yi Zhi. 1994; 93: 441–444. PMID: 7920087

266. Leblanc A, Leclercq B, Nitenberg G, Lasser P, Couanet D, Hartmann O, et al. [Acute hemorrhagic pancreatitis caused by asparaginase. A case in a child with a favorable course]. Presse Medicaire Paris Fr 1983. 1983; 12: 1351–1353.
269. Schuler D, Koós R, Révész T, Virág I, Gálf I. L-asparaginase therapy and its complications in acute lymphoid leukaemia and generalized lymphosarcoma. Haematologia (Budap). 1976; 10: 205–211.

270. Khanna S, Kumar A. Acute pancreatitis due to hydrocortisone in a patient with ulcerative colitis [2]. J Gastroenterol Hepatol Aust. 2003; 18: 1110–1111.

271. Achevar JL, Rivero FM, Cobo RJ, Ruiz Del Arbol OL. Doxycycline induced-acute pancreatitis. Med Clin (Barc). 2010; 134: 705–706.

272. Inayat F, Virk HUH, Yoon DJ, Riaz I. Drug-Induced Pancreatitis: A Rare Manifestation of Doxycycline Administration. North Am J Med Sci. 2016; 8: 117–120.

273. Goffin E, Horsmans Y, Pirson Y, Cornu C, Geubel A, van Ypersele De Strihou C. Acute necrotico-hemorrhagic pancreatitis after famciclovir prescription. Transplantation. 1995; 59: 1218–1219. PMID: 7537399

274. Dabaghi S. ACE inhibitors and pancreatitis. Ann Intern Med. 1991; 115: 330–331.

275. Kanbay M, Sutcu H, Yilmaz U, Boyacioglu S. Recurrent acute pancreatitis probably secondary to lisinopril. South Med J. 2006; 99: 1388–1389. https://doi.org/10.1097/01.smj.0000251413.20573.ad PMID: 17733197

276. Miller LG, Tan G. Drug-induced pancreatitis (lisinopril). J Am Board Fam Pract. 1999; 12: 150–153. https://doi.org/10.3122/jabfm.12.2.150 PMID: 10220239

277. Nakaoka H, Shinohara T, Ito H, Matsumoto K, Kato Y. Acute pancreatitis associated with the use of lisinopril. Ann Pharmacother. 1993; 27: 1465–1466. https://doi.org/10.1177/107868139302701211 PMID: 8305779

278. Standridge JB. Fulminant pancreatitis associated with lisinopril therapy. South Med J. 1994; 87: 179–181. https://doi.org/10.1097/00007611-199409000-00005 PMID: 8158779

279. Gaffney S, Walker C, Quigley P, Quigley G, Lewis H. Acute pancreatitis associated with the use of lisinopril. J Emerg Med. 2001; 21: 340–341. https://doi.org/10.1016/s0736-4679(01)00272-4 PMID: 11532275

280. McFadden M, Gordon A, Leong G, Ward D, Scott JG. Pancreatitis associated with metformin use for management of clozapine-related weight gain. Aust N Z J Psychiatry. 2016; 50: 701–702. https://doi.org/10.1177/0004867416631893 PMID: 26883571

281. Molina Infante J, Prieto Bermejo AB, Perez GB, Fernandez BM. Toxic metformin-associated acute pancreatitis without kidney failure. Med Clin (Bari). 2006; 131: 519.

282. Calmus Y, Biour M, Bodin F. Indalpine-induced hepatitits and pancreatitis. Gastroenterology Clin Biol. 1985; 9: 266–268. PMID: 4007381

283. Lin YH, Peng CL, Lin HJ, Chang FY. Acute pancreatitis possibly related to finasteride. J Clin Gastroenterol. 2001; 32: 276.

284. Abdul-Ghaffar NU, el-Sonbaty MR. Pancreatitis and rhabdomyolysis associated with lovastatin-gemfibrozil therapy. J Clin Gastroenterol. 1995; 21: 340–341. https://doi.org/10.1097/0004836-199512000-00027 PMID: 8583121
294. Abraham A, Raghavan P, Patel R, Rajan D, Singh J, Mustacchia P. Acute pancreatitis induced by methimazole therapy. Case Rep Gastroenterol. 2012; 6: 223–231. https://doi.org/10.1159/000338652 PMID: 22679409

295. Agito K, Manni A. Acute Pancreatitis Induced by Methimazole in a Patient With Subclinical Hyperthyroidism. J Investig Med High Impact Case Rep. 2015; 3: 2324709615592229. https://doi.org/10.1177/2324709615592229 PMID: 26425645

296. Jung JH, Hahn JR, Jung J, Kim SK, Kim S, Kim KY, et al. Acute pancreatitis induced by methimazole treatment in a 51-year-old korean man: a case report. J Korean Med Sci. 2014; 29: 1170–1173. https://doi.org/10.3346/jkms.2014.29.8.1170 PMID: 25120331

297. Taguchi M, Yokota M, Koyano H, Endo Y, Ozawa Y. Acute pancreatitis and parotitis induced by methimazole in a patient with Grave's disease. Clin Endocrinol (Oxf). 1999; 51: 667–670.

298. Yang M, Qu H, Deng HC. Acute pancreatitis induced by methimazole in a patient with Graves' disease. Thyroid Off J Am Thyroid Assoc. 2012; 22: 94–96.

299. Kikuchi I, Miyata N, Yoshimura Y, Miyamoto K, Tachikawa N. Methimazole-induced acute pancreatitis: a case report. J Korean Med Sci. 2014; 29: 1170–1173. https://doi.org/10.3346/jkms.2014.29.8.1170 PMID: 30474825

300. Soylu AR, Dokmeci G, Tezel A, Cakir B, Umit H, Karahan N, et al. Lamivudine-induced acute pancreatitis in a patient with decompensated Hbv-related chronic liver disease. J Clin Gastroenterol. 2004; 38: 134. https://doi.org/10.1097/00004836-200402000-00010 PMID: 14754288

301. Tuon FF, de Fatima Guastini CM, Castro Boulos MI. Acute pancreatitis associated with lamivudine therapy for chronic B hepatitis. Braz J Infect Dis. 2008; 12: 263. https://doi.org/10.1590/s1413-86702008000400001 PMID: 1930723

302. Famularo G, De SC, Minisola G, Nicotra GC. Cross-reaction allergic pancreatitis with ketoprofen and flurbiprofen [1]. Pancreas. 2007; 35: 187–188. https://doi.org/10.1097/mpa.0b013e3180645d94 PMID: 17632327

303. Rodier JM, Pujade-Lauraine E, Batel-Copel L, Alexandre JH, Bernadou A. Granisetron-induced acute pancreatitis [1]. J Cancer Res Clin Oncol. 1996; 122: 132–133. https://doi.org/10.1007/bf01226272 PMID: 8576281

304. Julve Pardo R, Garcia-Escrig M, Catala Barcelo J, del Val JH, Fernandez Ponsati J. [Acute pancreatitis as an effect of IV methylprednisolone in the treatment of optical neuritis]. Neurol Barc Spain. 1998; 13: 372–373.

305. Sabre A, Guthrie MM, Maleknia R. Acute necrotising pancreatitis derived from low-dose corticosteroid use: an important reminder of clinical management. BMJ Case Rep. 2015. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med&NEWS=N&AN=26150628

306. Yoshizawa Y, Ogasa S, Izaki S, Kitamura K. Corticosteroid-induced pancreatitis in patients with autoimmune bullous disease: Case report and prospective study. Dermatol Basel Switz. 1999; 198: 304–306.

307. Bär S, Daudel F, Zueger T. Ominous triad triggered by high-dose glucocorticosteroid therapy. BMJ Case Rep. 2017; 2017. https://doi.org/10.1136/bcr-2017-220328 PMID: 28630246

308. Nango D, Nakashima H, Hirose Y, Shiina M, Echizen H. Causal relationship between acute pancreatitis and methylprednisolone pulse therapy for fulminant autoimmune hepatitis: a case report and review of literature. J Pharm Health Care Sci. 2018; 73: 645–646. https://doi.org/10.1007/s00228-017-2207-5 PMID: 28132081

309. Yahiaoui N, Roche M, Aissaoui-Hoffmann N, Keita BA, Mallaret M. Intravenous methylprednisolone induced acute pancreatitis. Eur J Clin Pharmacol. 2017; 73: 645–646. https://doi.org/10.1007/s00228-017-2207-5 PMID: 24690523

310. Arellano L, Altaba A, Santamaria C, Garcia-Vicente JA. [Acute pancreatitis in a patient treated with losartan]. Aten Primaria. 2014; 46: 316–317. https://doi.org/10.1016/j.aprim.2014.02.003 PMID: 24690523

311. Birck R, Keim V, Fiedler F, van der Woude FJ, Rohmeiss P. Pancreatitis after losartan. Lancet Lond Engl. 1998; 351: 1178.

312. Bosch X. Losartan-induced acute pancreatitis [8]. Ann Intern Med. 1997; 127: 1043–1044.

313. Erenoglu C, Ulutu lu AH, Top C, Akin ML, Celenk T. Do MRI agents cause or worsen acute pancreatitis? Ulus Travma Ve Acil Cerrahi Derg Turk J Trauma Emerg Surg TJTES. 2007; 13: 78–79.

314. Terzi C, Sokmen S. Acute pancreatitis induced by magnetic-resonance-imaging contrast agent. Lancet Lond Engl. 1999; 354: 1789–1790.

315. Morse D, Kumar N, Aisenberg G. Gadolinium-Induced acute pancreatitis. Consultant. 2018; 58: 257–258.
Birchfield GR, Ward JH, Redman BG, Flaherty L, Samlowski WE. Acute pancreatitis associated with high-dose interleukin-2 immunotherapy for malignant melanoma. West J Med. 1990; 152: 714–716. PMID: 2353479

Corey WA, Doebbeling BN, DeJong KJ, Britigan BE. Metronidazole-induced acute pancreatitis. Rev Infect Dis. 1991; 13: 1213–1215. https://doi.org/10.1093/clinids/13.6.1213 PMID: 1775854

Feola DJ, Thornton AC. Metronidazole-induced pancreatitis in a patient with recurrent vaginal trichomoniasis. Pharmacotherapy. 2002; 22: 1508–1510. https://doi.org/10.1592/phco.22.16.1508.33691 PMID: 12432979

Celfiarco A, Warschauer C, Burakoff R. Metronidazole-induced pancreatitis. Am J Gastroenterol. 1989; 84: 958–960. PMID: 2756988

Loulergue P, Mir O. Metronidazole-induced pancreatitis during HIV infection. AIDS Lond Engl. 2008; 22: 545.

Nigwekar SU, Casey KJ. Metronidazole-induced pancreatitis. A case report and review of literature. JOP J Pancreas. 2004; 5: 516–519.

Plotnick BH, Cohen I, Tsang T, Cullinan T. Metronidazole-induced pancreatitis. Ann Intern Med. 1985; 103: 891–892. https://doi.org/10.7326/0003-4819-103-6-891 PMID: 2415031

Romero Ganuzza FJ. Pancreatitis associated with metronidazole. Gastroenterol Hepatol. 2008; 31: 264–265.

Sanford KA, Mayle JE, Dean HA, Greenbaum DS. Metronidazole-associated pancreatitis. Ann Intern Med. 1988; 109: 756–757. https://doi.org/10.7326/0003-4819-109-9-756 PMID: 3263823

Sura ME, Heinrich KA, Suseno M. Metronidazole-associated pancreatitis. Ann Pharmacother. 2000; 34: 1152–1155. https://doi.org/10.1345/aph.10021 PMID: 11054984

Tsesmeli NE, Giannoulis KE, Savopoulos CG, Vretou EE, Ekonomou IA, Giannoulis EK. Acute pancreatitis as a possible consequence of metronidazole during a relapse of ulcerative colitis. Eur J Gastroenterol Hepatol. 2007; 19: 805–806. https://doi.org/10.1097/MEG.0b013e328133f2fb PMID: 17700268

VanWalraven AA, Edels M, Fong S. Pancreatitis caused by mefenamic acid. Can Med Assoc J. 1982; 126: 894.

Wurm S, Schreiber F, Spindelboeck W. Mefenamic acid: A possible cause of drug-induced acute pancreatitis. Pancreateol Off J Int Assoc Pancreateol IAP Al. 2015; 15: 570–572.

Roblin X, Abinader Y, Baziz A. [Acute pancreatitis induced by gliclazide]. Gastroenterol Clin Biol. 1992; 16: 96.

del Val Antonana A, Ble Caso M, Higon Ballester MD, Ortuno Cortes JA. Lacosamide-induced acute pancreatitis with positive rechallenge test. J Clin Gastroenterol. 2014; 48: 651.

Christophe JL. Pancreatitis induced by nitrofurantoin. Gut. 1994; 35: 712–713. https://doi.org/10.1136/gut.35.5.712 PMID: 8200574

Mouallem M, Sirotin T, Farfel Z. Nitrofurantoin-induced pancreatitis. Isr Med Assoc J. 2003; 5: 754–755. PMID: 14719480

Nelis GF. Nitrofurantoin-induced pancreatitis: report of a case. Gastroenterology. 1983; 84: 1032–1034. PMID: 6832555

Barthet M, Brunet P, Bernard JC, Dussol B, Rodor F, Jouglard J, et al. [Acute pancreatitis during treatment with meglumine antimoniate (Glucantime)]. Gastroenterol Clin Biol. 1994; 18: 90–92.

De LaIlla F, Pellizzer G, Gradoni L, Vespiogani M, Franzetti M, Stecca C. Acute pancreatitis associated with the administration of meglumine antimoniate for the treatment of visceral leishmaniasis [7]. Clin Infect Dis. 1993; 16: 730–731. https://doi.org/10.1093/clinids/16.5.730 PMID: 8507769

Kuyucu N, Kara C, Bakirtac A, Tezic T. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed pancreatitis caused by meglumine antimoniate. Pediatr Infect Dis J. 2001; 20: 455–457. https://doi.org/10.1097/00006454-200104000-00021 PMID: 11332679

Nwogbe B, Ferie J, Smith H, Gunawardena I, Dhatriya K. Significant lamotrigine overdose associated with acute pancreatitis. J R Soc Med. 2009; 102: 118–119. https://doi.org/10.1258/jrsm.2009.080314 PMID: 19297653
340. Garcia Aguilera X, Teruel Sanchez-Vegazo C, Crespo Perez L, Moreira Vicente V. [Orlistat-induced acute pancreatitis]. Med Clin (Barc). 2008; 130: 557.

341. Van der Heide H, Ten Haaf MA, Stricker BH. Pancreatitis caused by methyldopa. Br Med J Clin Res Ed. 1981; 282: 1930–1931. https://doi.org/10.1136/bmj.282.6280.1930 PMID: 6786677

342. Magill P, Ridgway PF, Conlon KC, Neary P. A case of probable ibuprofen-induced acute pancreatitis. J Pancreas. 2006; 7: 311–314.

343. Moslim MA, Sodeman TC, Nawras AT. A Case of Suggested Ibuprofen-Induced Acute Pancreatitis. Am J Ther. 2016; 23: e1918–e1921. https://doi.org/10.1097/MJT.0000000000000943. PMID: 27077468

344. Sevenuncan NO, Ozkan AE, Kayhan B. Linagliptin-related pancreatitis in a diabetic patient with biliary calculus: A case report. Medicine (Baltimore). 2018; 97: e13284. https://doi.org/10.1097/MD.00000000000013284 PMID: 30557974

345. Heluwaert F, Pofelski J, Germain E, Robin X. [Piroxicam and acute pancreatitis]. Gastroenterol Clin Biol. 2006; 30: 635–636. https://doi.org/10.1016/s0399-8320(06)73248-1 PMID: 16733395

346. Chen JL, Spinowitz N, Karwa M. Hypertriglyceridemia, acute pancreatitis, and diabetic ketoacidosis possibly associated with mirtazapine therapy: a case report. Pharmacotherapy. 2003; 23: 940–944. https://doi.org/10.1592/phco.23.7.940.32725 PMID: 27077468

347. Hussain A, Burke J. Mirtazapine associated with recurrent pancreatitis —a case report. J Psychopharmacol Oxf Engl. 2008; 22: 336–337.

348. Lankisch PG, Werner HM. Mirtazapine: Another drug responsible for drug-induced acute pancreatitis? A letter of warning. Pancreas. 2003; 26: 211. https://doi.org/10.1097/00006676-200303000-00021 PMID: 12604923

349. Bowers RD, Valaneejad SM, Holombo AA. Mirtazapine-Induced Pancreatitis -A Case Report. J Pharm Pract. 2018; 897190018760645. https://doi.org/10.1177/0897190018760645 PMID: 29486665

350. Guerra M. Toxicity of indomethacin. Report of a case of acute pancreatitis. JAMA. 1967; 200: 552–553. PMID: 6071455

351. Memis D, Akalin E, Yucel T. Indomethacin-induced pancreatitis: a case report. JOP J Pancreas. 2005; 6: 344–347.

352. Tobias PE, Varughese CA, Hanson AP, Gunmani PK. A Case of Linezolid Induced Toxicity. J Pharm Pract. 2018; 897190018782787. https://doi.org/10.1177/0897190018782787 PMID: 29911459

353. Anagnostopoulos GK, Tsiakas S, Marganitis G, Kostopoulos P, Arvanitidis D. Acute pancreatitis due to pravastatin therapy. J Pancreas. 2003; 4: 129–132.

354. Tsigrelis C, Pitchumoni CS. Pravastatin: a potential cause for acute pancreatitis. World J Gastroenterol. 2006; 12: 7055–7057. https://doi.org/10.3748/wjg.v12.i43.7055 PMID: 17109506

355. Di Martino V, Ezenfis J, Benhamou Y, Bernard B, Opolon P, Bricaire F, et al. Severe acute pancreatitis related to the use of neflinavir in HIV infection: report of a case with positive rechallenge. AIDS Lond Engl. 1999; 13: 1421–1423.

356. Midgard R, Ertresvag K, Trondsen E, Spigset O. Life-threatening acute pancreatitis associated with interferon beta-1a treatment in multiple sclerosis. Neurology. 2005; 65: 170–171.

357. Chis BA, Fodor D. Acute pancreatitis during GLP-1 receptor agonist treatment. A case report. Clujul Med 1957. 2018; 91: 117–119. https://doi.org/10.15386/cjmed-804 PMID: 29440961

358. Boruchowicz A, Gallon P, Foissey D, Gower P, Gamblin C, Cuignet P, et al. [Acute pancreatitis associated with corticosteroid treatment in Crohn's disease]. Gastroenterol Clin Biol. 2003; 27: 560–561. PMID: 12843925

359. Felig DM, Topazian M. Corticosteroid-induced pancreatitis. Ann Intern Med. 1996; 124: 1016.

360. Goldberg BH, Bergstein JM. Acute respiratory distress in a child after steroid-induced pancreatitis. Pediatrics. 1978; 61: 317–318. PMID: 634691

361. Hamed I, Lindeman RD, Czerwinska AW. Case report: acute pancreatitis following corticosteroid and azathioprine therapy. Am J Med Sci. 1978; 276: 211–219. https://doi.org/10.1097/00000441-197809000-00009 PMID: 739057

362. Riemenschneider TA, Wilson JF, Vernier RL. Glucocorticoid-induced pancreatitis in children. Pediatrics. 1968; 41: 428–437. PMID: 4295389

363. Safer L, El KA, Hochlaf S, Bdioui F, Halloul F, Saffar H. Acute pancreatitis in a patient receiving prednisone therapy [2]. Sem Hop. 1995; 71: 123–124.

364. Canovas B, de Luis DA, Beato P, Zurita P. [Acute lithiasic pancreatitis in patients treated with statins analogs]. Rev Clin Esp. 2000; 200: 182–183. https://doi.org/10.1016/s0001-2565(00)70601-1 PMID: 10804774
365. Fredenrich A, Sosset C, Bernard JL, Sadoul JL, Freychet P. Acute pancreatitis after short-term octreotide [6]. Lancet Lond Engl. 1991; 338: 52–53.
366. Gradon JD, Schulman RH, Chapnick EK, Sepkowitz DV. Octreotide-induced acute pancreatitis in a patient with acquired immunodeficiency syndrome. South Med J. 1991; 84: 1410–1411. https://doi.org/10.1097/00007611-199111000-00035 PMID: 1948240
367. Sadoul JL, Benchimol D, Thyss A, Freychet P. Acute pancreatitis following octreotide withdrawal. Am J Med. 1991; 90: 763–764. PMID: 2042694
368. Vidal J, Sacanella E, Munoz E, Miro JM, Navarro S. Acute pancreatitis related to octreotide in a patient with acquired immunodeficiency syndrome. Pancreas. 1994; 9: 395–397. https://doi.org/10.1097/00006676-199405000-00021 PMID: 8022766
369. Famularo G, Minisola G, Nicotra GC, De SC. Acute pancreatitis associated with irbesartan therapy [3]. Pancreas. 2005; 31: 294–295. https://doi.org/10.1097/01.mpa.0000178281.58158.64 PMID: 16163066
370. Lee HM, Villa AF, Caudrelier S, Garnier R. Can loperamide cause acute pancreatitis? Pancreas. 2011; 40: 780–781. https://doi.org/10.1097/MPA.0b013e31821fa52f PMID: 21673538
371. Agarwal M, Lunt H, Scott R. Hormone replacement therapy, diabetes and pancreatitis secondary to hypertriglyceridaemia. N Z Med J. 1997; 110: 426. PMID: 9418835
372. Blake WED, Pitcher ME. Estrogen-related pancreatitis in the setting of normal plasma lipids: case report. Menopause N Y N. 2003; 10: 99–101.
373. Youssef SS, Iskandar SB, Scruggs J, Roy TM. Acute pancreatitis associated with omeprazole. Int J Clin Pharmacol Ther. 2005; 43: 558–561. https://doi.org/10.5414/cpp43558 PMID: 16372517
374. Passier JLM, van Puijenbroek EP, Jonkers GJPM, van Grootheest AC. Pancreatitis associated with the use of itraconazole. Neth J Med. 2010; 68: 285–289. PMID: 20558653
375. Nishioka S de A, Guedes LQ. Possible lovastatin-induced fatal necrotizing pancreatitis. J Pharm Technol-n. 2003; 19: 283–286.
376. Falko JM, Thomas FB. Letter: Acute pancreatitis due to procainamide-induced lupus erythematosus. Ann Intern Med. 1975; 83: 832–833. https://doi.org/10.7326/0003-4819-83-6-832 PMID: 1200531
377. Bank S, Marks IN. Case reports. Hyperlipaemic pancreatitis and the pill. Postgrad Med J. 1960; 46: 576–578.
378. Devars du Mayne JF, Bouchacourt E, Hardouin JP. [Acute pancreatitis cholestatic hepatitis induced by estroprogestatives]. Nouv Presse Med. 1980; 9: 3550–3551.
379. Steiner RE, Orlowski RZ, Lee HC. Acute Pancreatitis Associated with Ixazomib in a Multiple Myeloma Patient. Acta Haematol. 2018; 139: 67–70. https://doi.org/10.1159/000484655 PMID: 29402766
380. Straumann A, Bauer M, Pichler WJ, Pirovino M. Acute pancreatitis due to pyritinol-induced sialadenitis, intrahepatic cholestasis and pancreatitis: an immune-mediated phenomenon. Gastroenterology. 1998; 115: 452–454. https://doi.org/10.1016/s0016-5085(98)70212-4 PMID: 9679051
381. Bosch JA, Valdes M, Oristrell J, Pigrau C, Ordi J. Acta Gastro-Ente rol Belg. 1985; 48: 529–530.
382. Flamenaubm A, Abergel A, Marcato N, Zenut M, Kemeny JL, Cassan P. [Regressive fulminant hepatitis, acute pancreatitis and renal insufficiency after taking ketoprofen]. Gastroenterol Clin Biol. 1998; 22: 975–976. PMID: 9881281
383. Maroy B. [Benign acute pancreatitis probably due to taking ketoprofen]. Therapie. 1998; 53: 602–603. PMID: 10070244
384. Rosenfeld GA, Chang A, Poulin M, Kwan P, Yoshida E. Cholestatic jaundice, acute kidney injury and acute pancreatitis secondary to the recreational use of methandrost folate: A case report. J Med Case Reports. 2011; 5: no.
385. Anagnostopoulos GK, Kostopoulos P, Tsiakos S, Margantis G, Anvaridis D. Fulminant pancreatitis associated with ramipril therapy. Pancreas. 2003; 27: 278–279. https://doi.org/10.1097/00006676-200310000-00007 PMID: 14508138
386. Kanbay M, Korkmaz M, Yilmaz U, Gur G, Boyacioglu S. Acute pancreatitis due to ramipril therapy. Postgrad Med J. 2004; 80: 617–618. https://doi.org/10.1136/pgmj.2003.018119 PMID: 15467001
387. Vallianou N, Geladari E, Trigkidis K, Skoula A, Kokkinakis E. Ramipril-induced acute pancreatitis a case report and literature review. Arch Hell Med. 2017; 34: 821–823.
388. Adam JP, Gauthier P, Letarte N. Safe administration of docetaxel after weekly paclitaxel-induced acute pancreatitis. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract. 2016. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medp&NEWS=N&AN=27468225
389. Kumar DM, Sundar S, Vasanthan S. A case of Paclitaxel-induced pancreatitis [1]. Clin Oncol. 2003; 15: 35.
390. McMahon MA, Kearns G, McCaffrey J, Grogan L. Association between paclitaxel and necrotic pancreatitis. Ir Med J. 2006; 99: no.

391. Raiss H, El Amarti L, Layachi M, Bruyas A, Boutayeb S, et al. Probable paclitaxel-induced pancreatitis: uncommon case report and literature review. J Gastrointest Oncol. 2017; 8: E80–E83. doi:10.21037/jgo.2017.08.06 PMID: 29299374

392. Famularo G, Bizzarri C, Nicotra GC. Acute pancreatitis caused by ketorolac tromethamine [3]. J Clin Gastroenterol. 2002; 34: 283–284. https://doi.org/10.1097/00004836-200203000-00021 PMID: 11513668

393. Goyal SB, Goyal RS. Ketorolac tromethamine-induced acute pancreatitis [1]. Arch Intern Med. 1998; 158: 411.

394. Sato K, Hayashi M, Utsugi M, Ishizuka T, Takagi H, Mori M. Acute pancreatitis in a patient treated with micafungin. Clin Ther. 2007; 29: 1468–1473. https://doi.org/10.1016/j.clinthera.2007.07.012 PMID: 17825698

395. Hermann R, Shaw RG, Fone DJ. Ranitidine-associated recurrent acute pancreatitis. Aust N Z J Med. 2000; 20: 243–244. https://doi.org/10.1111/j.1445-5994.1990.tb01028.x PMID: 2372274

396. Tan WW, Chapnick EK, Abter EL, Haddad S, Zimbalist EH, Lutwick LI. Paromomycin-associated pancreatitis in HIV-related cryptosporidiosis. Ann Pharmacother. 1995; 29: 22–24. https://doi.org/10.1177/106002809502900110 PMID: 7711341

397. Battaglia M, Ditonno P, Palazzo S, Bettocchi C, Garofalo L, Selvaggi FP. Lethal somatostatin analog-induced acute necrotizing pancreatitis in a patient with hormone-refractory prostate cancer. Scand J Urol Nephrol. 2006; 40: 423–425. https://doi.org/10.1080/00365590500342190 PMID: 17060090

398. Sequeira Lopes da Silva JT, Gonzalez Casas O, Bejarano Moguel V, Lobo Pascua M, Lopez-Santamaria Redondo A, Cordero Torres R. Lanreotide autogel-induced acute pancreatitis in a patient with acromegaly. Gastroenterol Hepatol. 2013; 36: 21–25.

399. Pandey K, Singh D, Lal CS, Das VNR, Lal CS. Fatal acute pancreatitis in a patient with visceral leishmaniasis during miltefosine treatment. J Postgrad Med. 2013; 59: 306–308. https://doi.org/10.4103/0022-3859.123161 PMID: 2346389

400. Chintanaboina J, Gopavaram D. Recurrent acute pancreatitis probably induced by rosuvastatin therapy: A case report. Case Rep Med. 2012; 2012: no.

401. Echinard E, Dupon M, Malou M, Ragnaud JM, Lacut JY, Albin H. [Acute fatal pancreatitis following treatment with pentamidine]. Therapie. 1986; 41: 520. PMID: 3810550

402. Foisy MM, Slayter KL, Hewitt RG, Morse GD. Pancreatitis during intravenous pentamidine therapy in an AIDS patient with prior exposure to didanosine. Ann Pharmacother. 1994; 28: 1025–1028. https://doi.org/10.1177/106002809402800905 PMID: 7803875

403. Hart CC. Aerosolized pentamidine and pancreatitis. Ann Intern Med. 1989; 111: 691.

404. Herer B, Chinet T, Labrune S, Collignon MA, Chretien J, Huchon G. Pancreatitis associated with pentamidine by aerosol. BMJ. 1989; 298: 605.

405. Kumar S, Schnadig VJ, MacGregor MG. Fatal acute pancreatitis associated with pentamidine therapy. Am J Gastroenterol. 1989; 84: 451–453. PMID: 2784222

406. Salah A, Lortholary O, Lhote F, Cohen P, Guillevin L. [Acute pancreatitis induced by pentamidine isethionate in aerosols]. Presse Med. 1993; 22: 49.

407. Harris AG, Caroli-Bosc FX, Demarquay JF, Hastier P, Delmont J. Acute pancreatitis in an octreotide-treated AIDS patient—suggested alternative mechanisms [4]. Pancreas. 1995; 11: 318–319. https://doi.org/10.1097/00006676-199510000-00019 PMID: 8577690

408. Murphey SA, Josephs AS. Acute pancreatitis associated with pentamidine therapy. Arch Intern Med. 1981; 141: 56–58. https://doi.org/10.1001/archinte.1981.00340010052013 PMID: 6969581

409. O’Neil MG, Selub SE, Hak LJ. Pancreatitis during pentamidine therapy in patients with AIDS. Clin Pharm. 1991; 10: 56–59. PMID: 199087

410. Pais JR, Cazorla C, Novo E, Viana A. Massive haemorrhage from rupture of a pancreatic pseudocyst after pentamidine-associated pancreatitis. Eur J Med. 1992; 1: 251–253. PMID: 1341455

411. Pauwels A, Eliaszewicz M, Larrey D, Lacassin F, Poireir JM, Meyohas MC, et al. Pentamidine-induced acute pancreatitis in a patient with AIDS. J Clin Gastroenterol. 1990; 12: 457–459. https://doi.org/10.1097/00004836-199008000-00022 PMID: 1697871

412. Salmeron S, Petitpretz P, Katlama C, Herve P, Brivet F, Simonneau G, et al. Pentamidine and pancreatitis. Ann Intern Med. 1986; 105: 140–141.

413. Sauleda J, Gea JG, Aguilar MC, Aran X, Pasto M, Broquetas JM. Probable pentamidine-induced acute pancreatitis. Ann Pharmacother. 1994; 28: 52–53. https://doi.org/10.1177/106002809402800111 PMID: 8123961
414. Singh G, el-Gadi SM, Sparks RA. Pancreatitis associated with aerosolised pentamidine. Genitourin Med. 1995; 71: 130–131. https://doi.org/10.1136/sti.71.2.130 PMID: 7744406

415. Villamil A, Hammer RA, Rodriguez FH. Edematous pancreatitis associated with intravenous pentamidine. South Med J. 1991; 84: 796–798. PMID: 2052980

416. Wood G, Wetzig N, Hogan P, Whitby M. Survival from pentamidine induced pancreatitis and diabetes mellitus. Aust N Z J Med. 1991; 21: 341–342. https://doi.org/10.1111/j.1445-5994.1991.tb04702.x PMID: 1935514

417. Zuger A, Wolf BZ, el-Sadr W, Simberkoff MS, Rahal JJ. Pentamidine-associated fatal acute pancreatitis. JAMA. 1986; 256: 2383–2385. PMID: 3490588

418. Kawakami H, Kubota Y, Ban T, Shibata N, Hosokawa A. Lenvatinib-induced acute pancreatitis associated with a pancreatic pseudocyst and splenic pseudoaneurysms. Pancreas. 2018; 47: e34–e35. https://doi.org/10.1097/MPA.0000000000001061 PMID: 29894425

419. Mori S, Ebihara K. A sudden onset of diabetic ketoacidosis and acute pancreatitis after introduction of mizoribine therapy in a patient with rheumatoid arthritis. Mod Rheumatol. 2008; 18: 634–638. https://doi.org/10.1007/s10165-008-0106-4 PMID: 1953514

420. Johnson JL, Loomis IB. A case of simvastatin-associated pancreatitis and review of statin-associated pancreatitis. Pharmacotherapy. 2006; 26: 414–422. https://doi.org/10.1592/phco.26.3.414 PMID: 16503723

421. Lons T, Chousterman M. [A new case of simvastatin-induced acute pancreatitis]. Gastroenterol Clin Biol. 1991; 15: 986–987.

422. Ramdani M, Schmitt AM, Liautard J, Duhamel O, Legroux P, Gislon J, et al. [Simvastatin-induced acute pancreatitis: two cases]. Gastroenterol Clin Biol. 1991; 15: 986.

423. Famularo G, Minisola G, Nicotra GC, De Simone C. Idiosyncratic pancreatitis associated with perindopril. JOP J Pancreas. 2005; 6: 605–607.

424. Gallego-Roj o FJ, Gonzalez-Calvin JL, Guilarte J, Casado-Caballero FJ, Bellot V. Perindopril-induced acute pancreatitis. Dig Dis Sci. 1997; 42: 1789–1791. https://doi.org/10.1023/a:1018838204781 PMID: 9286249

425. Knezevich E, Crnic T, Kershaw S, Drincic A. Liraglutide-associated acute pancreatitis. Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm. 2012; 69: 386–389.

426. Nakata H, Sugitani S, Yamaji S, Otsu S, Higashi Y, Ohtomo Y, et al. Pancreatitis with pancreatic tail swelling associated with incretin-based therapies detected radiologically in two cases of diabetic patients with end-stage renal disease. Intern Med Tokyo Jpn. 2012; 51: 3045–3049.

427. Das S, Mondal S, Dey JK, Bandyopadhyay S, Saha I, Tripathi SK. A case of montelukast induced hypercholesterolemia, severe hypertriglyceridemia and pancreatitis. J Young Pharm JYP. 2013; 5: 64–66. https://doi.org/10.1016/j.jyp.2013.06.002 PMID: 24023457

428. Amar S, Wu KJ, Tan WW. Sorafenib-induced pancreatitis [4]. Mayo Clin Proc. 2007; 82: 521.

429. Ayyildiz T, Aydin T, Eminler AT, Yildirim C, Irak K, Kiyici M, et al. Sorafenib-induced pancreatitis. J Exp Clin Med Turk. 2015; 32: 133–135.

430. Kobayashi Y, Kanemitsu T, Kamoto A, Satoh M, Mori N, Seki K, et al. Painless acute pancreatitis associated with sorafenib treatment: A case report. Med Oncol. 2011; 28: 463–465. https://doi.org/10.1007/s12032-010-9479-2 PMID: 20300970

431. Li M, Srinivas S. Acute pancreatitis associated with sorafenib. South Med J. 2007; 100: 909–911. https://doi.org/10.1097/SMJ.0b013e31813c695d PMID: 17902294

432. Sevin A, Chen A, Atkinson B. Tyrosine kinase inhibitor induced pancreatitis. J Oncol Pharm Pract. 2013; 19: 257–260. https://doi.org/10.1177/1078155212457968 PMID: 23034406
438. Kattah Martinez LX, Marin Carrillo LF, Rojas Melo L. Sorafenib-Induced Acute Pancreatitis in a Patient with Differentiated Thyroid Cancer. Eur Thyroid J. 2018; 7: 145–148. https://doi.org/10.1159/000483161 PMID: 30023347

439. Twohig P, Rivington J. Sorafenib-Induced Acute Pancreatitis: Case Report and Review of the Literature. J Gastrointest Cancer. 2019; 50: 137–142. https://doi.org/10.1007/s12029-017-9980-3 PMID: 28664318

440. Funayama Y, Fukushima K, Shibata C, Koyama K, Miura K, Takahashi K, et al. Acute pancreatitis complicating ulcerative colitis under administration of corticosteroid in surgical cases [3]. J Gastroenterol. 2004; 39: 592–594. https://doi.org/10.1007/s00535-004-1350-9 PMID: 15235881

441. Keefe M, Munro F. Acute pancreatitis: a fatal complication of treatment of bullous pemphigoid with systemic corticosteroids. Dermatologica. 1989; 179: 73–75. https://doi.org/10.1159/000248315 PMID: 2676630

442. Fathallah N, Zamy M, Slim R, Fain O, Hmouda H, Bouraoui K, et al. Acute pancreatitis in the course of meprobandate poisoning. JOP J Pancreas. 2011; 12: 404–406.

443. Einollahi B, Dolatimehr F. Acute pancreatitis induced by mycophenolate mofetil in a kidney transplant patient. J Nephroparmacology. 2015; 4: 72–74.

444. Klein SM, Khan MA. Hepatitis, toxic epidermal necrolysis and pancreatitis in association with sulindac therapy. J Rheumatol. 1983; 10: 512–513. PMID: 6224935

445. Lerche A, Vyberg M, Kirkegaard E. Acute cholangitis and pancreatitis associated with sulindac (Clinoril). Histopathology. 1987; 11: 647–653. https://doi.org/10.1111/j.1365-2559.1987.tb02675.x PMID: 3623432

446. Lilly EL. Pancreatitis after administration of sulindac. JAMA. 1981; 246: 2680. PMID: 7310962

447. Memon AN. Pancreatitis and sulindac. Ann Intern Med. 1982; 97: 139.

448. Siefkin AD. Sulindac and pancreatitis. Am J Med. 1980; 69: 93–94. PMID: 6276981

449. Sugerman HJ. Sulindac-induced acute pancreatitis mimicking gallstone pancreatitis. Am Surg. 1989; 55: 536–538. PMID: 2774359

450. Zygmont DJ, Williams HJ, Bienz SR. Acute pancreatitis associated with long-term sulindac therapy. West J Med. 1986; 144: 461–462. PMID: 3716404

451. Betrosian AP, Balla M, Papanikolaou M, Kofinas G, Georgiadis G. Post-operative pancreatitis after propofol administration [3]. Acta Anaesthesiol Scand. 2001; 45: 1052. https://doi.org/10.1034/j.1399-6576.2001.450824.x PMID: 11576064

452. Bird H, Brim V. Propofol and postoperative pancreatitis. Anaesthesia. 2000; 55: 506–507.

453. Bustamante SE, Appachi E. Acute pancreatitis after anesthesia with propofol in a child with glycogen storage disease type IA. Paediatr Anaesth. 2006; 16: 680–683. https://doi.org/10.1111/j.1460-9592.2005.01833.x PMID: 16719886

454. Gottschling S, Larsen R, Meyer S, Graf N, Reinhard H. Acute pancreatitis induced by short-term propofol administration. Paediatr Anaesth. 2005; 15: 1006–1008. https://doi.org/10.1111/j.1460-9592.2004.01562.x PMID: 16238566

455. Jawaid Q, Presti ME, Neuschwander-Tetri BA, Burton FR. Case report: Acute pancreatitis after single-dose exposure to propofol: A case report and review of literature. Dig Dis Sci. 2002; 47: 614–618. https://doi.org/10.1023/a:1017932522875 PMID: 11911351

456. Kumar AN, Schwartz DE, Lim KG. Propofol-induced pancreatitis: Recurrence of pancreatitis after rechallenge. Chest. 1999; 115: 1198–1199. https://doi.org/10.1378/chest.115.4.1198 PMID: 10208230

457. Leisure GS, O'Flaherty J, Green L, Jones DR. Propofol and postoperative pancreatitis. Anesthesiology. 1996; 84: 224–227. https://doi.org/10.1097/00000542-199601000-00027 PMID: 8572338

458. Muniraj T, Aslani HR. Hypertriglyceridemia independent propofol-induced pancreatitis. JOP J Pancreas. 2012; 13: 451–453.

459. Priya G, Bhagat H, Pandia MP, Chaturvedi A, Seth A, Goswami R. Can propofol precipitate pancreatitis in patients with Cushing's syndrome? Acta Anaesthesiol Scand. 2005; 49: 1381–1383. https://doi.org/10.1111/j.1399-6576.2005.00751.x PMID: 16146480

460. Ting TW, Lee JH. Acute pancreatitis after propofol infusion in a teenage patient. Anaesth Intensive Care. 2012; 40: 561–562. PMID: 22577931

461. Anderson PE, Ellis GGJ, Austin SM. Case report: metolazone-associated hypercalcemia and acute pancreatitis. Am J Med Sci. 1991; 302: 235–237. https://doi.org/10.1097/00000441-199110000-00008 PMID: 1928234
462. Fuchs JEJ, Keith MR, Galanos AN. Probable metolazone-induced pancreatitis. DICP Ann Pharmacother. 1989; 23: 711.

463. Shindano A, Marot L, Geubel AP. Nifuroxazide-induced acute pancreatitis: A new side-effect for an old drug? Acta Gastro-Enterol Belg. 2007; 70: 32–33.

464. Alagozlu H, Cindoruk M, Unal S. Tamoxifen-induced severe hypertriglyceridaemia and acute pancreatitis. Clin Drug Investig. 2006; 26: 297–302. https://doi.org/10.2165/00044011-200626050-00007 PMID: 17163263

465. Eliaf MS, Nakou K, Liamis G, Pavlidis NA. Tamoxifen-induced severe hypertriglyceridaemia and acute pancreatitis. Ann Oncol Off J Eur Soc Med Oncol. 2000; 11: 1067–1069.

466. Kim YA, Lee S, Jung JW, Kwon YJ, Lee GB, Shin DG, et al. Severe acute pancreatitis due to tamoxifen-induced hypertriglyceridemia with diabetes mellitus. Chin J Cancer Res Chung-Kuo Yen Chen Chiu. 2014; 26: 341–344. https://doi.org/10.3978/j.issn.1000-9604.2014.05.01 PMID: 25035662

467. Sakhri J, Salem CB, Harbi H, Fatallah N, Ltaief R. Severe acute pancreatitis due to tamoxifen-induced hypertriglyceridemia with positive rechallenge. J Pancreas. 2010; 11: 382–384.

468. Singh HK, Prasad MS, Kandasamy AK, Dharanipragada K. Tamoxifen-induced hypertriglyceridemia causing acute pancreatitis. J Pharmacol Pharmacother. 2016; 7: 38–40. https://doi.org/10.4103/0976-500X.179365 PMID: 24699039

469. Kataria PSC, Kendre PP, Patel AA, Bohra MZ, Tahiliani N. Tamoxifen Induced Pancreatitis: An Unusual Complication of Commonly used Drug. J Clin Diagn Res JCDR. 2017; 11: XD05–XD06. https://doi.org/10.7860/JCDR/2017/27440.1046 PMID: 28699260

470. Chang TG, Chiu NY, Hsu WY. Acute pancreatitis associated with quetiapine use in schizophrenia. J Psychopharmacol. 2014; 34: 382–383. https://doi.org/10.1097/JCP.0000000000000047 PMID: 24699039

471. Liou LS, Hung YJ, Hsieh CH, Hsiao FC. Aggravation of hypertriglyceridemia and acute pancreatitis in a bipolar patient treated with quetiapine. Yonsei Med J. 2014; 55: 831–833. https://doi.org/10.3349/ymj.2014.55.3.831 PMID: 24719155

472. Boyle MP. Minocycline-induced pancreatitis in cystic fibrosis. Chest. 2001; 119: 1283–1285. https://doi.org/10.1378/chest.119.4.1283 PMID: 11296204

473. Chetaille E, Delenserie R, Yzel T, Decocq G, Biour M, Andrejak M. [Minocycline involvement in two cases of acute pancreatitis]. Gastroenterol Clin Biol. 1998; 22: 555–556. PMID: 9762297

474. Gabriel JG, Bhogal S, Kapila A. Minocycline-Associated Pancreatitis. Am J Ther. 2018; 25: e556–e557. https://doi.org/10.1097/MJT.0000000000000635 PMID: 28767455

475. Drabo YJ, Niakara A, Ouedraogo H. [Acute pancreatitis secondary to administration or norfloxacin]. Ann Fr Anesth Reanim. 2002; 21: 68–69. https://doi.org/10.1016/s0750-7658(01)00562-7 PMID: 11878127

476. Ventura C, Urich R, Skinner S, Bina R, Chuang KY, Van Thiel DH, et al. First report of telaprevir-induced pancreatitis. Dig Dis Sci. 2013; 58: 887–888. https://doi.org/10.1007/s10620-013-2576-2 PMID: 23932743

477. Castro JL, Rabago LR, Vello R, Perez MD, Redondo M, Blesa C, et al. [Rifampicin as a cause of acute pancreatitis]. Rev Espanola Enfermedades Dig Organo Of Soc Espanola Patol Dig. 2000; 92: 822–823.

478. Pedregal M, Larraona JL, Tristancho A, Lopez T, Maraver A. Acute pancreatitis during naltrexone treatment [1]. Gastroenterol Hepatol. 1992; 15: 433–434.

479. Verma R. Naltrexone-Associated Acute Pancreatitis. Prim Care Companion CNS Disord. 2016; 18. https://doi.org/10.1097/PCC.1601953 PMID: 27922226

480. Murtaza G, Faqah A, Konowitz N, Lu H, Kuruvilla A, Adhikari S. Acute Pancreatitis Related to a Chemotherapy Drug. World J Oncol. 2017; 8: 18–19. https://doi.org/10.14740/wjon1066e PMID: 28983380

481. Elmore MF, Rogge JD. Tetracycline-induced pancreatitis. Gastroenterology. 1981; 81: 1134–1136. PMID: 6456964

482. Nicolau DP, Mendoza DE, Kline JJ. Tetracycline-induced pancreatitis. Am J Gastroenterol. 1991; 86: 1669–1671. PMID: 1951248

483. Torosio J, Vender R. Tetracycline-induced pancreatitis. J Clin Gastroenterol. 1987; 9: 580–581. https://doi.org/10.1097/00004836-198710000-00021 PMID: 3680912

484. Berent I, Carabeth J, Cordero MM, Cordero R, Sugarman B, Robinson D. Pancreatitis associated with risperidone treatment? [3]. Am J Psychiatry. 1997; 154: 130–131.
485. Cordeiro Q Jr, Elkis H. Pancreatitis and cholestatic hepatitis induced by risperidone. J Clin Pharmacol. 2001; 21: 529–530. https://doi.org/10.1097/00004714-200110000-00012 PMID: 11593080

486. Hanft A, Bourgeois J. Risperidone and pancreatitis. J Am Acad Child Adolesc Psychiatry. 2004; 43: 1458–1459. https://doi.org/10.1097/00004714-200408000-00032 PMID: 15564814

487. Kawabe K, Ueno SI. A case of acute pancreatitis associated with risperidone treatment. Clin Pharmacol Neurosci. 2011; 12: 67–68. https://doi.org/10.9758/cpn.2014.12.1.67 PMID: 24851124

488. Aygencel G, Akbuga B, Kekes A. Acute pancreatitis following naproxen intake. Eur J Emerg Med Off J Eur Soc Emerg Med. 2006; 13: 372.

489. Castiella A, Lopez P, Bujanda A, Arenas JI. Possible association of acute pancreatitis with naproxen. J Clin Gastroenterol. 1995; 21: 258. https://doi.org/10.1097/00004836-199510000-00022 PMID: 8648686

490. Du Ville L, Debeuckelaere S, Reynaert H, Devis G. Pancreatitis associated with naproxen. Am J Gastroenterol. 1993; 88: 464.

491. Wu SM, Wolf JW. Phenformin and pancreatitis. Ann Intern Med. 1978; 88: 128.

492. Bernas Albeniz A, Aveiga Valencia DA, Etxeberria Zabalza L, Zaldibar-Gernikagolita Bilaio J, Aguilera Celorio L. Acute pancreatitis in ICU following treatment with tigecycline. Rev Esp Anestesiol Reanim. 2017; 64: 46–49. https://doi.org/10.1016/j.redar.2016.05.006 PMID: 2769674

493. Gislon M, Moachon L, Jeanne L, Dumaine V, Eyrolle L, Morand P, et al. Acute pancreatitis related to tigecycline: case report and review of the literature. Scand J Infect Dis. 2008; 40: 681–683. https://doi.org/10.1080/03865530801938949 PMID: 18979610

494. Hung WY, Kogelman L, Volpe G, Iafrati M, Davidson L. Tigecycline-induced acute pancreatitis: case report and literature review. Int J Antimicrob Agents. 2009; 34: 486–489. https://doi.org/10.1016/j.ijantimicag.2009.05.004 PMID: 19540093

495. Lipshitz J, Kruh J, Cheung P, Cassagnol M. Tigecycline-induced pancreatitis. J Clin Gastroenterol. 2009; 43: 93.

496. Lin J, Wang R, Chen J. Tigecycline-induced acute pancreatitis in a renal transplant patient: a case report and literature review. BMC Infect Dis. 2018; 18: 201. https://doi.org/10.1186/s12879-018-3103-z PMID: 29720098

497. Saez-Royuela F, Pacho E, Hernandez D, Marin G. Acute pancreatitis caused by salazopyrine. Gastroenterol Hepatol. 1988; 11: 434–435.

498. Engel T, Justo D, Amritai M, Volchek Y, Mayan H. Nilotinib-associated acute pancreatitis. Ann Pharmacother. 2013; 47: e3. https://doi.org/10.1345/aph.1R334 PMID: 23300151

499. Yamada T, Nannya Y, Shimizu M, Seishima M, Tsurumi H. Symptomatic Acute Pancreatitis Induced by Nilotinib: A Report of Two Cases. Intern Med Tokyo Jpn. 2016; 55: 349–3497. https://doi.org/10.1007/s00277-007-0410-7 PMID: 18040684

500. Lee CF, Sun MS, Tai YK. Saxagliptin-induced recurrent acute pancreatitis. Intern Med Tokyo Jpn. 2014; 53: 1351–1354.

501. Baysal B, Kayar Y, Ozmen A, EiShobaky M, Mahdi N, Ince AT, et al. Olanzapine-induced acute pancreatitis. Turk J Gastroenterol. 2015; 26: 289–290. https://doi.org/10.5152/tjg.2015.0216 PMID: 26006214

502. Belli H, Sertbas Y, Bayik Y. Olanzapine-induced diabetes due to pancreatitis. Indian J Gastroenterol Off J Indian Soc Gastroenterol. 2005; 24: 273.
509. Buszek SM, Roy-Chaudhury P, Yadlapalli G. Olanzapine-induced hypertriglyceridemia resulting in necrotizing pancreatitis. ACG Case Rep J. 2016; 3: no.

510. Doucette DE, Grenier JP, Robertson PS. Olanzapine-induced acute pancreatitis. Ann Pharmacother. 2000; 34: 1128–1131. https://doi.org/10.1345/aph.19390 PMID: 11054978

511. Gupta A, Ghoshal UC, Mohindra S, Saraswat VA. Acute necrotizing pancreatitis following olanzapine therapy. Trop Gastroenterol Off J Dig Dis Found. 2014; 35: 132–134.

512. Rizos E, Tournikioti K, Alevy zakis E, Peppa M, Papazaxos K, Zorbas G, et al. Acute Necrotizing Pancreatitis Following Olanzapine Treatment and 759C/T Polymorphism of HTR2C Gene: A Case Report. Vivo Athens Greece. 2015; 29: 529–531.

513. Nishawala MA, Callaghan M, Malatack JJ, Moughan B, Ambrosini PJ, Price B, et al. Pancreatitis associated with serotonin-dopamine antagonists. J Child Adolesc Psychopharmacol. 1997; 7: 211–213. https://doi.org/10.1089/cap.1997.7.211 PMID: 9466237

514. Rossor AM, Leech N, Neely RD. Olanzapine-induced chylomiconemia presenting as acute pancreatitis. J Clin Psychopharmacol. 2007; 27: 395–396. https://doi.org/10.1097/01.jcp.0000264988.55603.bf PMID: 17632226

515. Samanta S, Banik K, Baronia AK. Emphysematous pancreatitis predisposed by Olanzapine. Indian J Anaesth. 2014; 58: 323–326. https://doi.org/10.4103/0019-5049.135049 PMID: 25024479

516. Waage C, Carlsson H, Nielsen EW. Olanzapine-induced pancreatitis: a case report. JOP J Pancreas. 2004; 5: 388–391.

517. Franga DL, Harris JA. Polyethylene glycol-induced pancreatitis. Gastrointest Endosc. 2000; 52: 789–791. https://doi.org/10.1067/mge.2000.109718 PMID: 11115922

518. Antonow DR. Acute pancreatitis associated with trimethoprim-sulfamethoxazole. Ann Intern Med. 1986; 104: 363–365. https://doi.org/10.7326/0003-4819-104-3-363 PMID: 2416721

519. Bartels RH, van der Spek JA, Oosten HR. Acute pancreatitis due to sulfamethoxazole-trimethoprim. South Med J. 1992; 85: 1006–1007. https://doi.org/10.1097/00007611-199210000-00018 PMID: 1411717

520. Cololina Aviles J, Quintana Tomas L, Arenas Gracia M, Llorca Martinez E. [Pancreatitis associated with cotrimoxazole in an HIV-positive patient]. An Med Interna Madr Spain 1984. 1997; 14: 487–488.

521. Cortes J, Arroyo E, Reus S, Climent E, Portilla J. Acute pancreatitis due to cotrimoxazole and HIV infection: A case report. Farm Hosp. 1999; 23: 325–326.

522. Floris-Moore MA, Amadio-Groton MI, Catalano MT. Adverse Reactions to Trimethoprim/Sulfamethoxazole in AIDS. Ann Pharmacother. 2003; 37: 1810–1813. https://doi.org/10.1345/aph.1D179 PMID: 14632594

523. Holla S, Ommurugan B, Amita D, Bairy KL, Saravu K, Madireddi J. A rare case of Cotrimoxazole induced acute pancreatitis, acute kidney injury and crystalluria (APAKIC). Res J Pharm Biol Chem Sci. 2016; 7: 1099–1102.

524. Park TY, Oh HC, Do JH. A case of recurrent pancreatitis induced by trimethoprim-sulfamethoxazole re-exposure. Gut Liver. 2010; 4: 250–252. https://doi.org/10.5009/gnl.2010.4.2.250 PMID: 20559530

525. Versleijen MJW, Naber AHJ, Riksen NP, Wanten GJ, Debruyne FMJ. Recurrent pancreatitis after trimethoprim-sulfamethoxazole rechallenge. Neth J Med. 2005; 63: 275–277. PMID: 16093580

526. Jung M, Kim J, Lee JY, Kim M, Kim S-H, Ahn K. Trimethoprim-sulfamethoxazole induces acute pancreatitis associated with drug-specific cytotoxic T lymphocytes. J Allergy Clin Immunol Pract. 2019; 7: 336–338. https://doi.org/10.1016/j.jaip.2018.06.009 PMID: 29940316

527. Cortes E, Ribera E, Cucurull E, de Otero J, Ocana I, Pahissa A. [Acute pancreatitis due to antimonia ls in patients with visceral leishmaniasis and HIV infection]. Med Clin (Barc). 1995; 104: 578–580.

528. Domingo P, Ferrer S, Kolle L, Munoz C, Rodriguez P. Acute pancreatitis associated with sodium stibogluconate treatment in a patient with human immunodeficiency virus [5]. Arch Intern Med. 1996; 156: 1029. https://doi.org/10.1001/archinte.156.9.1029 PMID: 8624172

529. Donovan KL, White AD, Cooke DA, Fisher DJ. Pancreatitis and palindromic arthropathy with effusions associated with sodium stibogluconate treatment in a renal transplant recipient. J Infect. 1990; 21: 107–110. https://doi.org/10.1016/0163-4453(90)90830-2 PMID: 2166765

530. Gasser Jr, Magill AJ, Oster CN, Franke ED, Grogl M, Berman JD. Pancreatitis induced by pentavalent antimonal agents during treatment of leishmaniasis. Clin Infect Dis. 1994; 18: 83–90. https://doi.org/10.1093/clinids/18.1.83 PMID: 7519887

531. Halim MA, Alfurayh O, Kain ME, Dammans S, Al-Eisa A, Damanhouri G. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in a renal transplant recipient after the occurrence of pancreatitis due to stibogluconate. Clin Infect Dis. 1993; 16: 397–399. https://doi.org/10.1093/clinids/16.3.397 PMID: 8135901
532. McBride MO, Linney M, Davidson RN, Weber JN. Pancreatic necrosis following treatment of leishmaniasis with sodium stibogluconate. Clin Infect Dis Off Publ Infect Dis Soc Am. 1995; 21: 710.

533. McCarthy AE, Keystone JS, Kain KC. Pancreatitis occurring during therapy with stibogluconate: Two case reports [23]. Clin Infect Dis. 1993; 17: 952–953. https://doi.org/10.1093/clinids/17.5.952 PMID: 7741821

534. Santos J, Rivero A, Marquez M. [Acute pancreatitis with a fatal evolution due to antimonials in patients with visceral leishmaniasis and HIV infection]. Am Med Interna Madr Spain 2000; 17: 562–563.

535. Valencia ME, Laguna F, Gonzalez Lahoz J. [Nephrotic syndrome and acute pancreatitis related to glucantime administration]. An Med Interna Madr Spain 1984. 2000; 17: 54.

536. Das S, Ganguly A, Ghosh A, Mondal S, Dey JK, Saha I. Oral pantoprazole-induced acute pancreatitis in an 11-year-old child. Ther Drug Monit. 2012; 34: 242–244. https://doi.org/10.1097/FTD.0b013e3182526e6a PMID: 22495426

537. Lopes Mondejar P, Soto MP, Vences F, Hidalgo AM. Acute pancreatitis after pregabalin administration. Endocrinol Nutr. 2007; 54: 340.

538. Muluneh B, Buie LW, Collichio F. Vemurafenib-associated pancreatitis: case report. Pharmacotherapy. 2013; 33: e43–e44. https://doi.org/10.1002/phar.1208 PMID: 23436544

539. Abdullah AM, Scott RB, Martin SR. Acute pancreatitis secondary to 5-aminosalicylic acid in a child with ulcerative colitis. J Pediatr Gastroenterol Nutr. 1993; 17: 441–444. https://doi.org/10.1097/00005176-199311000-00019 PMID: 8145103

540. Aubry A, Alandry C, Lemiere C. [Acute pancreatitis during treatment with salazosulfapyridine]. Presse Medicale Paris Fr 1983. 1989; 18: 80.

541. Delgado Fontaneda E, Garcia Campos F, Ruiz Rebollo L, Ibarra Pena B, Moreto Canela M. [Acute pancreatitis caused by salazopyrine. An unusual association]. Rev Espanola Enfermedades Dig Organo Of Soc Espanola Patol Dig. 1991; 79: 439–440.

542. Faintuch J, Mott CB, Machado MC. Pancreatitis and pancreatic necrosis during sulfasalazine therapy. Int Surg. 1985; 70: 271–272. PMID: 7909645

543. Rubin R. Sulfasalaz ine-induced fulminant hepatic failure and necrotizing pancreatitis. Am J Gastroenterol. 1994; 89: 789–791. PMID: 8746057

544. Collet T, Even C, Peytier A, Piquet MA, Dao T, Verwaerde JC. [Acute pancreatitis and propylthiouracil]. Gastroent erol Clin Biol. 1995; 19: 952. PMID: 8746057

545. Croizet O, Louvel D, Teuliere JP, Buscail L, Escourrou J, Frexinos J. [Acute pancreatitis induced by valproic acid]. Gastroenterol Clin Biol. 1994; 18: 910–911. PMID: 7875411

546. Evans RJ, Miranda RN, Jordan J, Krolkowski FJ. Fatal acute pancreatitis caused by valproic acid. Am J Forensic Med Pathol. 1995; 16: 62–65. https://doi.org/10.1097/00000433-199503000-00014 PMID: 7771387

547. Fecik SE, Stoner SC, Raphael J, Lindsey C. Recurrent acute pancreatitis associated with valproic acid use for mood stabilization [9]. J Clin Psychopharmacol. 1999; 19: 483–484. https://doi.org/10.1097/00004714-199910000-00021 PMID: 10505958
557. Grauso-Eby NL, Goldfarb O, Feldman-Winter LB, McAbee GN. Acute pancreatitis in children from Valproic acid: case series and review. Pediatr Neurol. 2003; 28: 145–148. https://doi.org/10.1016/s0887-8994(02)00517-9 PMID: 12699868

558. Guevara-Campos J, Gonzalez-Guevara L, Vacaro-Bolivar I, Rojas JM. Acute pancreatitis associated to the use of valproic acid. Arq Neuropsiquiatr. 2009; 67: 513–515. https://doi.org/10.1590/s0004-282x2009000300028 PMID: 19623456

559. Houben ML, Wilting I, Stronk H, van Dijken PJ. Pancreatitis, complicated by a pancreatic pseudocyst associated with the use of valproic acid. Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc. 2005; 9: 77–80.

560. Jetha MM, Fiorillo L. Xanthomatosis and diabetes in an adolescent with familial dysbetalipoproteinemia 9 yr after valproate-induced pancreatitis. Pediatr Diabetes. 2012; 13: 444–447. https://doi.org/10.1111/j.1399-5448.2011.00843.x PMID: 22251869

561. Kayemba Kay’s Kabangu S, Bovier Lapierre M, Jalaguier E. [Acute pancreatitis and valproic acid]. Pediatrie. 1991; 46: 839–843. PMID: 1667041

562. dos Santos BL, Fernandes RMF, Neves FF. Valproic acid-induced pancreatitis in an adult. Arq Neuropsiquiatr. 2010; 68: 135–136. https://doi.org/10.1590/s0004-282x2010000100029 PMID: 20339670

563. Lott JA, Bond LW, Bobo RC, McClung HJ, Murray RD. Valproic acid-associated pancreatitis: report of three cases and a brief review. Clin Chem. 1990; 36: 395–397. PMID: 2105864

564. Moreiras Plaza M, Rodriguez Goyanes G, Cuina L, Alonso R. On the toxicity of valproic acid. Clin Nephrol. 1999; 51: 187–189. PMID: 10099893

565. Murphy MJ, Lyon IW, Taylor JW, Mitts G. Valproic acid associated pancreatitis in an adult. Arq Neuropsiquiatr. 2010; 68: 135–136. https://doi.org/10.1590/s0004-282x2010000100029 PMID: 20339670

566. Lott JA, Bond LW, Bobo RC, McClung HJ, Murray RD. Valproic acid-associated pancreatitis: report of three cases and a brief review. Clin Chem. 1990; 36: 395–397. PMID: 2105864

567. Ng JY, Disney AP, Jones TE, Purdie G. Acute pancreatitis and sodium valproate. Med J Aust. 1982; 2: 362. PMID: 6815441

568. Otusbo S, Huruzono T, Kobae H, Yoshimi S, Miyata K. Pancreatitis with normal serum amylase associated with sodium valproate: a case report. Brain Dev. 1995; 17: 219–221. https://doi.org/10.1016/0387-7604(95)00025-7 PMID: 7573766

569. Ozaydin E, Yukselgungor H, Kose G. Acute hemorrhagic pancreatitis due to the use of valproic acid in a child. Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc. 2008; 12: 141–143.

570. Sinclair DB, Berg M, Breault R. Valproic acid-induced pancreatitis in childhood epilepsy: case series and review. J Child Neurol. 2004; 19: 498–502. https://doi.org/10.1177/0883073804190070401 PMID: 15526953

571. Talwar D. Valproate-associated acute pancreatitis in a child with neuronal ceroid lipofuscinosis. J Child Neurol. 1994; 9: 36–37.

572. Williams LH, Reynolds RP, Emery JL. Pancreatitis during sodium valproate treatment. Arch Dis Child. 1983; 58: 543–544. https://doi.org/10.1136/adc.58.7.543 PMID: 6409011

573. Wyllie E, Wyllie R, Cruse RP, Erenberg G, Rothner AD. Pancreatitis associated with valproic acid therapy. Am J Dis Child 1960. 1984; 138: 912–914.

574. Yazdani K, Lippmann M, Gala I. Fatal pancreatitis associated with valproic acid: Review of the literature. Medicine (Baltimore). 2002; 81: 305–310.

575. Patrick KA, Jarriel JT, Hieger MA. Pancreatic Pseudo cyst Due to Acute Valproic Acid Overdose. Am J Ther. 2018; 25: e584–e585. https://doi.org/10.1097/MJT.0000000000000694 PMID: 29033479
581. Quan W, Shao Q, Zhang H, Liu F-H, Zhang X-H. Acute Pancreatitis Associated with Valproate Treatment. Chin Med J (Engl). 2018; 131: 1889–1890. https://doi.org/10.4103/0366-6999.237390 PMID: 30058594

582. Rose E, de Miscault G, Thome M, Boussard N. [Acute pancreatitis caused by sodium valproate. Review of the literature apropos of a case in a child]. Pediatr. 1991; 46: 831–837. PMID: 1667040

583. Droy VE, Sidi I, Korczyn AD. Riluzole-induced pancreatitis. Neurology. 1999; 52: 892–893. https://doi.org/10.1212/wnl.52.4.892 PMID: 10078757

584. Ianiro G, Cammarota G, Milani A, Mettimmato M, Gasbarini A. Moderately severe acute pancreatitis associated with riluzole. J Clin Gastroenterol. 2014; 48: 563.

585. Rodrigo L, Moreno M, Calleja S, Mateos V, Andrade RJ, Lucena MI. Riluzole-induced acute pancreatitis [5]. Am J Gastroenterol. 1999; 94: 2268–2269. https://doi.org/10.1111/j.1572-0241.1999.003982.x PMID: 11467672

586. Bauters T, Mondelaers V, Robays H, De Wilde H, Benot Y, De Moerloose B. Methemoglobinemia and hemolytic anemia after rasburicase administration in a child with leukemia. Int J Clin Pharm. 2013; 35: 303–305. https://doi.org/10.1007/s11096-010-9447-0 PMID: 21057874

587. Can B, Sali M, Batman A, Yilmaz H, Korkmaz U, Celebi A, et al. Valsartan-induced acute pancreatitis. Intern Med Tokyo Jpn. 2014; 53: 703–705.

588. Amaravadi RK, Jacobson BC, Solomon DH, Fischer MA. Acute pancreatitis associated with rofecoxib [18]. Am J Gastroenterol. 2002; 97: 1077–1078. https://doi.org/10.1111/j.1572-0241.2002.05646.x PMID: 12003405

589. Sato K, Yamada E, Uehara Y, Takagi H, Mori M. Possible role for human leukocyte antigen haplotype in rofecoxib-associated acute pancreatitis and cholestatic hepatitis. Clin Pharmacol Ther. 2006; 80: 554–555. https://doi.org/10.1016/j.clpt.2006.08.007 PMID: 17112814

590. Markov M, Patel K, Raeesy A, Bant A, Van Thiel DH, Nadir A. Liver and pancreatic injury induced by antituberculous therapy. Dig Dis Sci. 2007; 52: 3275–3281. https://doi.org/10.1007/s10620-005-9017-9 PMID: 17909976

591. Philip A, Sivaprasakam P, Sagar TG, Ganesan P. Voriconazole-induced pancreatitis in a patient of acute myeloid leukemia and invasive aspergillosis. J Pediatr Hematol Oncol. 2012; 34: 406. https://doi.org/10.1097/MPH.0b013e318257dc7a PMID: 22713708

592. Slim R, Salem CB, Zamy M, Fathallah N, Raynaud JJ, Bouraoui K, et al. Secnidazole-induced acute pancreatitis: A new side-effect for an old drug? J Pancreas. 2010; 11: 85–86.

593. Mirete G, Masia M, Gutierrez F, Mora A, Escolano C, Maestre A. Acute pancreatitis as a complication of ritonavir therapy in a patient with AIDS. Eur J Clin Microbiol Infect Dis. 1998; 17: 810–811. https://doi.org/10.1007/s10096-005-9017-9 PMID: 9923528

594. Ratkovic M, Basic-Jukic N, Radunovic D. Possible Sirolimus-Induced Acute Pancreatitis in a Renal Transplant Recipient. Ther Apher Dial. 2016; 20: 208–209. https://doi.org/10.1111/tad.12371 PMID: 26752587

595. Souweine B, Fialip J, Ruivard M, Amairtre O, Lavarenne J, Philippe P. Acute pancreatitis associated with roxithromycin therapy [3]. DICP Ann Pharmacother. 1991; 25: 1137.

596. Liu PH, Lee BJ, Wang CY, Hung DZ. Acute pancreatitis after severe theophylline overdose. Clin Toxicol Phila Pa. 2008; 46: 1103.

597. Anand H, Parthasarathi G, Selvan P, Stavudine-induced pancreatitis followed by lopinavir-ritonavir-induced pancreatitis. J Postgrad Med. 2008; 54: 153–155. https://doi.org/10.4103/0022-3859.40788 PMID: 18480538

598. Cadranel JF, Grippon P, Lunel F, Victor N, Opolon P. [Ingestion of tiaprofenic acid (Surgam) associated with an outbreak of acute pancreatitis]. Gastroenterol Clin Biol. 1987; 11: 99–100. PMID: 356966

599. Oflazoglu U, Varol U, Alacacioglu A, Salman T, Demir N, Semiz HS, et al. Case report of a renal cell carcinoma patient with acute pancreatitis under both sunitinib and axitinib treatment. J Oncol Sci. 2016; 2: 63–65.

600. Hegazi MO, Saleh F, John JE. Is it tinidazole-induced pancreatitis? J Clin Pharm Ther. 2015; 40: 607–608. https://doi.org/10.1111/jcpt.12307 PMID: 26174560

601. Knackstedt C, Winograd R, Koch A, Abuzahra F, Trautwein C, Wasmuth HE. Acute necrotic pancreatitis induced by severe hypercalcemia due to tacalcitol ointment. Br J Dermatol. 2007; 156: 576–577. https://doi.org/10.1111/j.1365-2133.2006.07658.x PMID: 17300254

602. Picardo S, So K, Venugopali K, Chin M. Vedolizumab-induced acute pancreatitis: the first reported clinical case. BMJ Case Rep. 2018; 2018. https://doi.org/10.1136/bcr-2017-222554 PMID: 29305366
603. Baffoni L, Durante V, Grossi M. Acute pancreatitis induced by telmisartan overdose [3]. Ann Pharmacother. 2004; 38: 1088.

604. Girgis CM, Champion BL. Vildagliptin-induced acute pancreatitis. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2011; 17: e48–e50.

605. Flaig T, Douros A, Bronder E, Klimpel K, Greve R. Tolctizumab-induced pancreatitis: case report and review of data from the FDA Adverse Event Reporting System. J Clin Pharm Ther. 2016; 41: 718–721. https://doi.org/10.1111/jcpt.12456 PMID: 27670839

606. Nadir A, Nadir F, Hassanein T, Gurakar A, Wright HI, Van Thiel DH. Acute relapsing pancreatitis induced with ursodeoxycholic acid therapy. J Okla State Med Assoc. 1995; 88: 295–298. PMID: 7650564

607. Sevastru S, Wakatsuki M, Fennell J, Grocott MPW. Plasma exchange in the management of a case of hypertriglyceridaemic pancreatitis triggered by venlafaxine. BMJ Case Rep. 2012; 2012. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=22892234

608. Mahto SK, Gupta PK, Taneja RS, Singh A. Zidovudine-induced lactic acidosis with acute pancreatitis and myopathy: Lethal and rare complications. Indian J Pharmacol. 2018; 50: 212–214. https://doi.org/10.4103/ijp.IJP_285_18 PMID: 30505059

609. Yang SH, McNeely MJ. Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone. J Psychiatry. 2002; 159: 1435.

610. Delcenserie R. [What are the criteria for imputation of drug-induced pancreatitis?]. Gastroenterol Clin Biol. 2001; 25: 1S18–1S21. PMID: 11223590

611. Thaker SJ, Sinha RS, Gogtay NJ, Thatte UM. Evaluation of inter-rater agreement between three causality assessment methods used in pharmacovigilance. J PharmacoI Pharmacother. 2016; 7: 31–33. https://doi.org/10.4103/0976-500X.179361 PMID: 27127394

612. Bekiarie E, Rizava C, Athanasiadou E, Papaheodorou K, Liakos A, Karagiannis T, et al. Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. Endocrine. 2016; 52: 458–480. https://doi.org/10.1007/s12020-015-0841-1 PMID: 26714458

613. Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin. 2011; 27: 57–64. https://doi.org/10.1185/0300795.2011.602964 PMID: 22106978

614. Giorda CB, Nada E, Tartaglino B, Marafetti L, Gnavi R. A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position. Diabetes Obes Metab. 2014; 16: 1041–1047. https://doi.org/10.1111/dom.12297 PMID: 24702687

615. Poropat G, Archibugi L, Korpela T, Cárdenas-Jaén K, de-Madaria E, Capurso G. Statin use is not associated with an increased risk of acute pancreatitis–A meta-analysis of observational studies. United Eur Gastroenterol J. 2018; 6: 1206–1214. https://doi.org/10.1177/2050640618781168 PMID: 30288283

616. Greenhalgh T. How to read a paper. Getting your bearings (deciding what the paper is about). BMJ. 1997; 315: 243–246. https://doi.org/10.1136/bmj.315.7102.243 PMID: 9253275